Avoidant Restrictive Food Intake Disorder

Psychiatric MONDO:7770002 Pathograph 21 Show in embeddings browser Eating Disorder Mental Health Disorder

Avoidant/restrictive food intake disorder (ARFID) is a feeding and eating disorder characterized by persistent failure to meet nutritional and/or energy needs due to avoidance or restriction of food intake, in the absence of body-image disturbance or drive for thinness. Restriction is driven by one or more of three DSM-5 presentations: sensory sensitivity to the taste, texture, smell, or appearance of food; an apparent lack of interest in eating or low appetite; and fear of aversive consequences of eating (such as choking or vomiting). The absence of weight- and shape-related motivation is the key contrast with anorexia nervosa. ARFID was introduced in DSM-5 (2013), replacing and expanding the former "feeding disorder of infancy or early childhood," and shows strong neurodevelopmental (autism, ADHD) and anxiety-disorder comorbidity.

Ask OpenScientist

Ask a research question about Avoidant Restrictive Food Intake Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
13
Phenotypes
21
Pathograph
2
Genes
4
Medical Actions
4
Subtypes
2
Differentials
6
Trials
33
References
2
Deep Research
◆

Subtypes

4
Sensory-sensitivity presentation
Avoidance based on sensory properties of food and rigid preferences. A clinical presentation that can overlap with the other dimensions, not a separate Mendelian disorder.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"The Sensory subtype was characterised by high probabilities of sensory sensitivity (0.83) and rigid eating behaviours (0.73)"
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Empirically derived sensory class in secondary-care children and adolescents.
Lack-of-interest presentation
Low appetite or interest in eating and difficulty consuming sufficient amounts; can coexist with sensory sensitivity or fear.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"The Lack of Interest subtype was characterised by high probabilities of lack of appetite (0.85) and lack of interest in eating or food (1.0)"
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. The class distinguishes low appetite from other reasons for restriction.
Fear-of-aversive-consequences presentation
Avoidance motivated by anticipated choking, vomiting, pain or other aversive effects; may have relatively acute onset in clinical cohorts.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"The Fear subtype was characterised by high probability of fear of aversive consequences of eating (0.97)"
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Empirical clinical grouping; not a separate diagnostic category or proof that every case follows a traumatic event.
Combined presentation
Co-occurring dimensions are common. The largest class in a UK and Republic of Ireland secondary-care study combined sensory sensitivity and lack of interest. That study-specific class does not define a universal fourth biological subtype.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"the most prevalent class, comprising 38% of the sample, was the Combined Subtype characterised by a combination of Lack of Interest Subtype and Sensory Subtype."
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. The class distribution depends on the study population and ascertainment.
⚙

Pathophysiology

8
Multifactorial Genetic and Environmental Liability
A Swedish twin study estimated substantial genetic liability for a broad childhood ARFID phenotype defined from parent reports and health registers. Its best-fitting model estimated heritability of 0.79 (95% CI 0.70-0.85) and a nonshared environmental contribution of 0.21 (95% CI 0.15-0.30). Ascertainment emphasized sensory restriction, did not directly assess every diagnostic exclusion, and included a sibling-contrast parameter. These estimates do not identify causal genes or establish equal heritability across ages and ARFID presentations. Common-variant studies also support genetic contributions to avoidant/restrictive eating, but use different ascertainment: ARFI traits in a Norwegian population cohort and an algorithm-derived risk score in an autism cohort. Neither establishes a single causal pathway or a diagnostic genetic test for ARFID.
Downstream
Sensory Sensitivity and Food Selectivity Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
Low Appetite and Lack of Interest in Eating Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
Fear of Aversive Consequences of Eating Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
Show evidence (3 references)
PMID:36723946 SUPPORT Human Clinical
"The heritability of ARFID was 0.79 (95% CI, 0.70-0.85), with significant contributions from nonshared environmental factors (0.21; 95% CI, 0.15-0.30)."
Estimate for a broadly defined phenotype in Swedish twins aged 6-12 years; this is population-level variance partitioning, not individual risk or molecular evidence of a polygenic mechanism.
PMID:41284261 SUPPORT Human Clinical
"SNV heritability (SNV-h2) estimates on the liability scale ranged from 8% to 16%"
Common-variant estimates for parent-reported restrictive-eating phenotypes; these are not directly comparable with the Swedish twin heritability estimate.
PMID:34177659 SUPPORT Human Clinical
"the proband ARFID Score was estimated to have significant SNP h2 of 0.45 (95% CI: 0.13–0.76)"
Estimate for an algorithm-derived score in autistic probands, with a wide interval; it is not heritability of clinically diagnosed ARFID in the general population.
Sensory Sensitivity and Food Selectivity
Sensory-based avoidance of food limits accepted variety. A fasting visual-food-cue fMRI study found higher anterior cingulate and sensory association cortex activation in the sensory-sensitivity group, but no greater insula activation than healthy controls. These are brain-region associations from a passive viewing task, not evidence of taste-receptor-cell dysfunction or a proven causal sensory circuit. Full and subthreshold ARFID were included, and phenotype groups overlapped.
Downstream
Restriction and Avoidance of Food Intake Sensory aversion is modeled as one upstream driver of the core restriction/avoidance behavior.
Show evidence (2 references)
PMID:38849953 SUPPORT Human Clinical
"Individuals with ARFID may limit food variety and intake due to avoidance based on the sensory characteristics of the food"
Narrative-review evidence supports sensory-based avoidance as one of the core drivers of restricted intake in ARFID.
PMID:39964683 SUPPORT Human Clinical
"The ARFID-sensory sensitivity group did not show greater insula activation vs HC but showed greater activation of the ACC"
fMRI food-cue evidence supports a distinct cortical sensory-processing activation pattern in the sensory-sensitivity ARFID phenotype.
Low Appetite and Lack of Interest in Eating
Low interest in eating, low hunger and early satiation can limit intake. Within the lack-of-interest phenotype group, greater symptom severity correlated with lower right hypothalamus activation during a fasting visual-food-cue task. The group did not show lower hypothalamus activation than healthy controls overall. This cross-sectional association does not establish hypothalamic dysfunction as the cause of restriction or identify the responsible endocrine cell type. In a separate self-report study, ARFID severity correlated with lower anticipatory pleasure even after food items were removed. This broader reward association and the contribution of depressive symptoms do not establish a food-specific reward defect or its causal direction.
Downstream
Restriction and Avoidance of Food Intake Low appetite / lack of interest is modeled as a second upstream driver of restricted intake.
Poor Appetite The low-interest/appetite presentation has poor appetite as a clinical manifestation.
Show evidence (6 references)
PMID:34423319 SUPPORT Human Clinical
"including sensory sensitivity, lack of interest in eating or food, and fear of aversive consequences."
The structured interview assesses lack of interest as one presentation; ARFID as a whole is not limited to low appetite.
PMID:39964683 SUPPORT Human Clinical
"greater lack of interest was associated with lower hypothalamus activation in the ARFID-lack of interest group"
Within-group association between symptom severity and lower right hypothalamus response; the lack-of-interest group did not differ from controls overall.
PMID:37950288 SUPPORT Human Clinical
"greater endorsement of the lack of interest in food profile was related to lower anticipatory pleasure"
Exploratory association with self-reported anticipatory pleasure, including analyses without food items. The full-scale profile association was not significant after covariate adjustment; this is not proof of a food-specific reward mechanism.
+ 3 more references
Fear of Aversive Consequences of Eating
Fear of choking, vomiting, pain or another aversive consequence can maintain food avoidance. In a fasting visual-food-cue study, participants with the fear phenotype showed greater left-amygdala activation than healthy controls at the region-of-interest level. Fear severity did not correlate significantly with amygdala activation, and the phenotype contrast was not significant in the whole-brain analysis. Findings are associations and do not establish a specific neuronal subtype or prove that a prior adverse event caused the observed response.
Downstream
Restriction and Avoidance of Food Intake Fear of aversive consequences is modeled as a third upstream driver of restricted intake.
Show evidence (7 references)
PMID:38849953 SUPPORT Human Clinical
"related to any adverse consequences of eating"
Narrative-review evidence identifies fear of adverse consequences of eating as a distinct driver of avoidance in ARFID.
PMID:39964683 SUPPORT Human Clinical
"The ARFID-fear group showed greater amygdala activation vs HC"
fMRI evidence supports fear-circuit (amygdala) hyperactivation in the fear-of-aversive-consequences ARFID phenotype.
PMID:40568462 SUPPORT REVIEW SYNTHESIS Other
"Antecedents include gastrointestinal diseases and symptoms, traumatic events and experiences, dietary adversities history, and nutritional misconceptions."
Concept analysis of heterogeneous adult GI studies identifies candidate antecedents. The authors state that causal direction between GI disease and ARFID remains unresolved; medically necessary restriction alone does not establish ARFID.
+ 4 more references
Neurodevelopmental and Anxiety-Disorder Comorbidity
Autism spectrum disorder, ADHD and anxiety disorders can co-occur with ARFID. Autism was more frequent in sensory and combined presentations, while anxiety was more frequent in the fear presentation in a secondary-care surveillance cohort. These associations provide clinical context, not proof that a comorbid diagnosis causes a particular ARFID presentation.
Downstream
Sensory Sensitivity and Food Selectivity Proposed modifying context; observational comorbidity does not establish causal direction.
Fear of Aversive Consequences of Eating Proposed modifying context; observational comorbidity does not establish causal direction.
Show evidence (2 references)
PMID:36527163 SUPPORT Human Clinical
"Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%)."
Systematic-review evidence supports high anxiety-disorder and autism comorbidity in children and adolescents with ARFID.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"The Combined subtype and the Sensory subtype had significantly more ASD than the other two classes"
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Presentation-associated comorbidity in clinician-reported secondary-care cases; applicability outside this ascertainment is uncertain.
Restriction and Avoidance of Food Intake
The convergent core behavior: persistent avoidance or restriction of food intake reached by any of the three drivers, critically without the drive for thinness, fear of weight gain, or body-image disturbance that defines anorexia nervosa. This absence of weight/shape motivation is the defining contrast with anorexia nervosa. The three drivers are dimensional and frequently co-occur rather than being mutually exclusive subtypes: an empirical latent-class analysis of 319 children/adolescents found a mixed (combined) presentation to be the single most common class.
Downstream
Failure to Meet Nutritional and Energy Needs Restricted/avoidant intake is modeled upstream of nutritional and energy failure.
Restrictive Eating The pathophysiologic restriction behavior maps to the clinical restrictive-eating phenotype.
Feeding Difficulties Restricted range and amount of food manifest as feeding difficulties.
Psychosocial Impairment Related to Eating Avoidance of food and eating situations can impair social participation and family functioning.
Show evidence (4 references)
PMID:38849953 SUPPORT Human Clinical
"without the intention of losing weight and concerns of body image"
Narrative-review evidence supports the defining feature that ARFID restriction occurs without weight-loss intent or body-image concern, distinguishing it from anorexia nervosa.
PMID:36723946 SUPPORT Human Clinical
"with fear of weight gain as an exclusion"
The twin-study ARFID phenotype definition explicitly excludes fear of weight gain, reinforcing the absence of weight/shape motivation.
PMID:38333539 SUPPORT Human Clinical
"LCA revealed four distinct classes which were labelled as Fear subtype, Lack of Interest subtype, Sensory subtype, and Combined subtype."
National-surveillance latent-class analysis empirically recovers the three DSM-5 drivers plus a combined class, supporting the convergent multi-driver model of ARFID restriction.
+ 1 more reference
Failure to Meet Nutritional and Energy Needs
Inadequate energy or nutrient intake can cause weight loss, growth faltering and nutrient deficiencies. Severe or prolonged undernutrition can impair cardiovascular, gastrointestinal, skeletal and pubertal function. These consequences vary with the degree and pattern of restriction; ARFID can also present through psychosocial impairment without low weight.
Downstream
Weight Loss Nutritional/energy failure manifests as weight loss.
Failure to Thrive Nutritional compromise can contribute to this clinical consequence.
Anemia Nutritional compromise can contribute to this clinical consequence.
Bradycardia Nutritional compromise can contribute to this clinical consequence.
Constipation Nutritional compromise can contribute to this clinical consequence.
Delayed Puberty Nutritional compromise can contribute to this clinical consequence.
Amenorrhea Nutritional compromise can contribute to this clinical consequence.
Reduced Bone Mineral Density Nutritional compromise can contribute to this clinical consequence.
Show evidence (2 references)
PMID:36723946 SUPPORT Human Clinical
"an extremely limited range and/or amount of food eaten, resulting in the persistent failure to meet nutritional and/or energy needs"
Twin-study evidence supports restricted intake producing persistent failure to meet nutritional and energy needs.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"These symptoms are attributed to deficiencies in macronutrients and micronutrients"
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Clinical review connects the severe physical manifestations with inadequate nutrient intake.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Avoidant Restrictive Food Intake Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Blood 1
Anemia HP:0001903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anemia (HP:0001903). HP:0001903 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"The diagnosis of ARFID is made when the individual fails to meet appropriate nutritional requirements (such as anemia and vitamin deficiency)"
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. The clinical review identifies anemia among nutritional consequences.
Cardiovascular 1
Bradycardia HP:0001662 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bradycardia (HP:0001662). HP:0001662 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"electrolyte abnormalities (e.g., hypokalemia), dry skin, lanugo, alopecia, bradycardia, orthostatic postural tachycardia, hypotension, and a sunken abdomen."
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. These findings are described in severe ARFID-related malnutrition, not as universal features.
Digestive 3
Poor Appetite HP:0004396 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Poor appetite (HP:0004396). HP:0004396 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode SUPPORT Human Clinical
"The Lack of Interest subtype was characterised by high probabilities of lack of appetite (0.85) and lack of interest in eating or food (1.0)"
Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Poor appetite is characteristic of this presentation, not universal across ARFID.
Feeding Difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36723946 SUPPORT Human Clinical
"an extremely limited range and/or amount of food eaten"
Twin-study characterization of ARFID as extremely limited range/amount of food eaten supports feeding difficulties as a phenotype.
Constipation HP:0002019 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Constipation (HP:0002019). HP:0002019 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"fatigue, lethargy, difficulty concentrating, memory deficits, presyncope, constipation, hypersensitivity to cold, hypothermia"
Clinical review lists constipation among manifestations of severe malnutrition.
Endocrine 1
Delayed Puberty HP:0000823 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed puberty (HP:0000823). HP:0000823 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"female patients with ARFID may experience pubertal delay before the onset of menstruation."
The cited clinical description concerns females; no frequency or cross-sex generalization is assigned.
Genitourinary 1
Amenorrhea HP:0000141 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Amenorrhea (HP:0000141). HP:0000141 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"Primary amenorrhea may occur, and in postmenarcheal patients, secondary amenorrhea may result from low body weight."
The review distinguishes failure to start menstruating from cessation after menarche.
Musculoskeletal 1
Reduced Bone Mineral Density HP:0004349 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced bone mineral density (HP:0004349). HP:0004349 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"Primary amenorrhea may occur, and in postmenarcheal patients, secondary amenorrhea may result from low body weight. These findings are associated with lower bone mineral density."
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. The adjacent text describes delayed puberty and amenorrhea; this does not establish osteoporosis in every patient.
Nervous System 3
Restrictive Eating HP:0020302 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Restrictive eating (HP:0020302). HP:0020302 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"Individuals with ARFID may limit food variety and intake due to avoidance based on the sensory characteristics of the food"
Narrative-review evidence supports restriction/limitation of food variety and intake as the defining ARFID phenotype.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Recorded as a co-occurring clinical feature; the evidence does not establish that ARFID causes this finding.
Show evidence (1 reference)
PMID:36527163 SUPPORT Human Clinical
"Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%)"
Systematic-review evidence supports anxiety disorders as a common ARFID comorbidity.
Autistic Behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Recorded as a co-occurring clinical feature; the evidence does not establish that ARFID causes this finding.
Show evidence (1 reference)
PMID:36527163 SUPPORT Human Clinical
"Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%)."
Systematic-review evidence supports autism spectrum disorder as a common ARFID comorbidity.
Growth 2
Weight Loss HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38753906 SUPPORT Human Clinical
"ARFID is characterized by significant limitations in food intake leading to malnutrition, weight loss, or nutritional deficiency"
Clinical overview explicitly supports weight loss rather than equating all low weight with weight loss.
Failure to Thrive HP:0001508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"failure to achieve expected and adequate growth or delayed growth"
Growth faltering is a diagnostic consequence distinct from weight loss.
🧬

Genetic Associations

2
ADCY3 association with avoidant/restrictive food-intake traits (Genome-wide association with an ARFI-clinical trait definition; relationship to formally diagnosed ARFID remains unresolved)
Gene: ADCY3 hgnc:234 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ADCY3 (hgnc:234). hgnc:234 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: UNKNOWN
Show evidence (3 references)
PMID:41284261 SUPPORT Human Clinical
"One gene, ADCY3, located on chromosome 2, was associated with ARFI-clinical at 3 or 8 years"
Gene-based association after multiple-testing correction; the phenotype is explicitly narrower in diagnostic ascertainment than ARFID.
PMID:41284261 SUPPORT Human Clinical
"Therefore, phenotypes should not be interpreted as ARFID diagnoses, but as ARFID traits, accompanied by additional co-occurring indicators of clinical significance for ARFI-clinical."
Authors explicitly limit the diagnostic interpretation of the association.
PMID:41284261 SUPPORT Human Clinical
"Future studies are needed to replicate associations between individual genetic variants and avoidant/restrictive eating and investigate the biological mechanisms underlying these associations."
No specific ARFID causal mechanism or clinically validated genetic test is established.
Locus near ZSWIM6 associated with an ARFID risk score in autism (Nearest-gene annotation of a genome-wide signal for an algorithm-derived ARFID score in autistic probands)
Gene: ZSWIM6 hgnc:29316 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ZSWIM6 (hgnc:29316). hgnc:29316 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: UNKNOWN
Show evidence (3 references)
PMID:34177659 SUPPORT Human Clinical
"One SNP on chromosome 5, rs13177031 (p = 1.6 × 10−8), reached genome wide significance"
Genome-wide association with the proband risk score, not a Mendelian disease variant.
PMID:34177659 SUPPORT Human Clinical
"Genome-wide association revealed a single hit near ZSWIM6, a gene previously implicated in neurodevelopmental conditions."
Nearest-gene annotation only; neither variant-to-gene regulation nor a causal ARFID role was demonstrated.
PMID:34177659 SUPPORT Human Clinical
"it was not well-situated to conclusively distinguish ARFID risk factors from those of other eating disorders."
The study acknowledges diagnostic specificity limitations of self- and parent-reported phenotyping.
💊

Medical Actions

4
Cognitive-Behavioral Therapy for ARFID (CBT-AR)
Action: cognitive behavior therapy for ARFID (CBT-AR)NCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cognitive behavior therapy for ARFID (CBT-AR), annotated with Cognitive Behavior Therapy (NCIT:C64345). NCIT:C64345 is a clinical intervention from the NCI Thesaurus. Ontology label: Cognitive Behavior Therapy NCIT:C64345
Platform: Behavioral / lifestyle
CBT-AR combines regular eating, nutritional planning, presentation-specific exposure and relapse prevention. Sensory sensitivity is addressed through repeated food tasting, fear through graded exposure, and lack of interest through interoceptive exposure. Small uncontrolled outpatient studies in youth and adults reported lower ARFID severity and greater food variety; these studies establish feasibility and preliminary benefit, not comparative efficacy.
Mechanism Target:
Sensory Sensitivity and Food Selectivity — Repeated tasting and sensory exposure address food selectivity.
Show evidence (1 reference)
PMID:34423319 SUPPORT Human Clinical
"Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures."
The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
Fear of Aversive Consequences of Eating — Graded exposure addresses feared consequences and avoidance.
Show evidence (1 reference)
PMID:34423319 SUPPORT Human Clinical
"Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures."
The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
Low Appetite and Lack of Interest in Eating — Interoceptive exposure addresses the low-interest presentation.
Show evidence (1 reference)
PMID:34423319 SUPPORT Human Clinical
"Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures."
The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
Show evidence (6 references)
PMID:34423319 SUPPORT Human Clinical
"Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures."
The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
PMID:32776570 SUPPORT Human Clinical
"Of 25 eligible individuals, 20 initiated treatment, including 17 completers and 3 dropouts."
Uncontrolled feasibility study in medically stable youth aged 10-17; most received family-supported CBT-AR with medical monitoring.
PMID:32776570 SUPPORT Human Clinical
"ARFID severity scores (on the Pica, ARFID, and Rumination Disorder Interview) significantly decreased per both patient and parent report. Patients incorporated a mean of 16.7 (SD = 12.1) new foods from pre- to post-treatment."
Within-person improvements in the youth pilot; the absence of a control group prevents attribution of improvement specifically to CBT-AR.
+ 3 more references
Family-Based Treatment (FBT-ARFID)
Action: Family TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Family Therapy (NCIT:C93347). NCIT:C93347 is a clinical intervention from the NCI Thesaurus. NCIT:C93347
Platform: Behavioral / lifestyle
Family-based treatment adapted for ARFID trains caregivers to change restrictive eating, followed by return to age-appropriate self-management. A randomized trial of 98 medically stable, underweight children aged 6-12 compared 14 telehealth sessions over four months with individual psychoeducational motivational therapy. FBT-ARFID produced greater weight gain, but overall ARFID symptom severity improved similarly in both groups. This trial does not establish efficacy across adult or non-underweight populations.
Show evidence (2 references)
PMID:42019720 SUPPORT Human Clinical
"A total of 98 children with ARFID were randomized to 14 sessions of telehealth FBT-ARFID or PMT conducted over 4 months."
Randomized active-comparator trial in underweight children aged 6-12; assessments were masked, but weight, height and behavioral outcomes relied on parent reports.
PMID:42019720 SUPPORT Human Clinical
"FBT-ARFID was superior to PMT at EOT in promoting increased %EBW. There were no differences between groups regarding improvements in overall severity of ARFID symptoms or other related ARFID symptoms"
Preserves the distinction between the positive primary weight outcome and the absence of overall symptom superiority. Baseline-severity moderation was exploratory.
Nutritional Rehabilitation and Enteral Feeding
Action: nutritional rehabilitation with enteral tube feedingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is nutritional rehabilitation with enteral tube feeding, annotated with Nutritional Intervention (NCIT:C67022). NCIT:C67022 is a clinical intervention from the NCI Thesaurus. Ontology label: Nutritional Intervention NCIT:C67022
Platform: Other
Individualized dietetic rehabilitation restores adequate energy, fluids and micronutrients, initially using accepted foods and oral supplements when needed. Enteral support may be necessary for severe restriction or malnutrition and is reassessed as oral intake improves. Refeeding requires monitoring for electrolyte abnormalities and clinical instability.
Mechanism Target:
Failure to Meet Nutritional and Energy Needs — Accepted foods and oral or enteral supplementation restore nutritional intake.
Show evidence (1 reference)
PMID:38849953 SUPPORT Human Clinical
"This can be achieved through the consumption of foods that are more readily accepted by the individual, as well as the prescription of nutritional supplements via oral or enteral nutrition."
Supports accepted foods and individualized supplementation during nutritional rehabilitation.
Show evidence (2 references)
PMID:38849953 SUPPORT Human Clinical
"This can be achieved through the consumption of foods that are more readily accepted by the individual, as well as the prescription of nutritional supplements via oral or enteral nutrition."
Supports accepted foods and individualized supplementation during nutritional rehabilitation.
PMID:38849953 SUPPORT Human Clinical
"close monitoring for electrolyte abnormalities, which may arise from refeeding syndrome—a serious and potentially fatal complication—is essential"
Supports monitoring during nutritional rehabilitation because refeeding can cause dangerous electrolyte abnormalities.
Adjunctive Off-Label Pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: mirtazapine CHEBI:6950 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mirtazapine (CHEBI:6950). CHEBI:6950 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Medication is used selectively alongside behavioral and nutritional treatment to address appetite, nausea, anxiety or psychiatric comorbidity. Mirtazapine has case-based and retrospective inpatient evidence. Olanzapine, buspirone, fluoxetine and cyproheptadine have been described in small reports or combined-treatment series, which cannot isolate drug effects. No ARFID-specific medication is established by these studies.
Show evidence (5 references)
PMID:38849953 SUPPORT Human Clinical
"There is currently no psychotropic medication for treatment of ARFID approved by the U.S. Food and Drug Administration."
The 2024 review reports no FDA-approved ARFID pharmacotherapy; the cited medication evidence concerns off-label use.
PMID:38849953 SUPPORT Human Clinical
"reported the use of mirtazapine to enhance appetite and facilitate weight gain while reducing nausea and vomiting"
Narrative-review evidence supports off-label mirtazapine as an appetite-stimulating agent used in ARFID.
PMID:40265508 SUPPORT Human Clinical
"Hospital records from 87 children and adolescents with ARFID treated in an inpatient medical stabilization program were analyzed."
Retrospective inpatient study; 38 patients received mirtazapine. Prescribing was not randomized, concurrent treatment was intensive, and systematic adverse-effect assessment was unavailable.
+ 2 more references
🔬

Biochemical Markers

2
Fasting plasma cholecystokinin
Show evidence (4 references)
PMID:35830620 SUPPORT Human Clinical
"Fasting CCK was higher in those with full/subthreshold ARFID versus HCs with a large effect"
Case-control elevation after adjustment for age, sex and BMI percentile.
PMID:35830620 SUPPORT Human Clinical
"Within the ARFID group, CCK was not significantly related to BMI percentile, subjective appetite ratings, or ARFID characteristic measures."
The initial study did not establish that higher CCK tracked subjective appetite or clinical severity within ARFID.
PMID:42159358 SUPPORT Human Clinical
"However, there was no significant difference between the groups in fasting CCK at Baseline or Year 2."
The lack-of-interest presentation contrast was significant at only one follow-up, not consistently across timepoints.
+ 1 more reference
Fasting plasma ghrelin
Show evidence (2 references)
PMID:42159358 SUPPORT Human Clinical
"there were no differences in fasting ghrelin between participants that met versus did not meet cut-off for ARFID-lack of interest across timepoints."
Preserves the negative presentation-specific comparison.
PMID:42159358 SUPPORT Human Clinical
"greater increases in fasting ghrelin from Baseline to Years 1 and 2 were associated with greater decreases in ARFID severity scores at Years 1 (f2 = .15) and 2 (f2 = .23), respectively."
The reported association held at both annual follow-ups, but causal direction and treatment relevance remain untested.
🔬

Diagnosis

3
Clinical diagnostic assessment
Assess persistent restriction or avoidance with at least one significant consequence: weight loss or growth faltering, nutrient deficiency, reliance on supplements or enteral feeding, or marked psychosocial impairment. Assess food availability and cultural practices, weight/shape motivations, and medical or psychiatric explanations. A coexisting disorder does not preclude ARFID when the feeding disturbance exceeds what that condition usually explains and warrants additional attention.
Show evidence (3 references)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"Criterion B states that the eating disorder cannot be better explained by the unavailability of food or a culturally accepted practice."
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Food access and cultural practice are diagnostic exclusions.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"When an eating disorder occurs in the context of another condition or disorder, its severity exceeds that usually associated with the condition or disorder and warrants additional clinical attention"
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Clarifies diagnostic coexistence with medical and psychiatric conditions.
PMID:38718975 SUPPORT Human Clinical
"avoidant/restrictive eating by volume/variety resulting in any of the following consequences: (a) weight loss/failure to gain weight; (b) nutritional deficiency; (c) supplemental feeding dependence; and (d) psychosocial impairment"
Operational diagnostic assessment in a primary clinical study; impairment is not restricted to underweight.
PARDI interview and dimensional screening
The Pica, ARFID, and Rumination Disorder Interview assesses diagnosis, severity and all three overlapping presentations. NIAS and PARDI-AR-Q questionnaires can support screening and monitoring; screening alone does not establish that diagnostic exclusions are met.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"PARDI is a structured interview developed to assess the presence and severity of diagnoses for evaluation and treatment planning in clinical and research settings, specifically focusing on ARFID."
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Supports the structured interview.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode SUPPORT Human Clinical
"The NIAS addresses food restriction behaviors associated with the three eating patterns related to ARFID, namely appetite, fear, and sensory sensitivity."
Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Supports dimensional screening rather than a stand-alone diagnostic biomarker.
Nutritional and medical evaluation
Review growth trajectories, weight change, diet variety, vital signs and signs of nutrient deficiency. Laboratory evaluation is guided by dietary omissions, nutritional status and possible alternative diagnoses; brain imaging and appetite-hormone assays are research measures rather than established ARFID diagnostic tests.
Show evidence (1 reference)
PMID:38753906 SUPPORT Human Clinical
"Diagnosis involves a comprehensive medical, nutritional, and psychological evaluation to assess the patient's physical health, eating behaviors, and mental well-being."
Supports multidisciplinary assessment of the clinical syndrome.
🩻

Imaging Findings

2
Greater frontal cortical thickness in children with ARFID-like symptoms
Cross-sectional Generation R analysis found greater frontal and superior frontal cortical thickness in children with ARFID-like symptoms; the differences persisted after BMI adjustment. Classification used an index rather than a diagnostic interview. No significant regional volume or surface-area differences were found in the prespecified regions, and exploratory findings did not survive multiple-comparison correction.
Mri
frontal cortex UBERON:0001870 Uberon multi-species anatomy ontology (UBERON)
Research association, not an individual diagnostic marker. The study does not establish impaired synaptic pruning or causal executive dysfunction. Full-text results and Table 1 report 121 children with symptoms and 1,856 without; the abstract has an inconsistent comparator count.
Show evidence (3 references)
PMID:39623765 SUPPORT Human Clinical
"Neuroanatomical findings identified significantly greater frontal (p = .00743; d = 0.21) and superior frontal (p = 6.56E-04; d = 0.28) cortical thickness among children with ARFID symptoms."
The abstract reports a cortical-thickness association, not evidence for a cellular lesion.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode SUPPORT Human Clinical
"No observable differences in the regional surface area or volume of hypothesised regions were identified."
Full text of PMID:39623765 (Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.) retrieved through PMC/BioC. Preserves the negative anatomical outcomes.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode SUPPORT Human Clinical
"As such, the work in this study is unable to provide conclusive information regarding neural correlates associated with a clinical ARFID diagnosis, meaning the full generalisability to youth formally diagnosed with ARFID is unknown."
Full text of PMID:39623765 (Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.) retrieved through PMC/BioC. Index-defined symptom group in a population cohort; clinical diagnostic generalization remains unresolved.
Reduced food-cue anterior cingulate response following CBT-AR
An exploratory analysis of an uncontrolled CBT-AR pilot found reduced right anterior cingulate food-versus-object activation in participants with paired scans. Baseline activation did not significantly predict symptom change or remission; anterior insula and amygdala activation did not significantly change. The anterior cingulate change no longer reached conventional significance after exploratory adjustment for trait anxiety.
Functional Mri
anterior cingulate cortex UBERON:0009835 Uberon multi-species anatomy ontology (UBERON)
Research treatment correlate, not proof of a causal treatment mechanism or a treatment-selection biomarker. This is a subset of previously published CBT-AR and neurobiology participants, not an independent replication.
Show evidence (4 references)
PMID:41803077 SUPPORT Human Clinical
"youth with ARFID viewed images of food and non-food in a fasted state at pre-treatment (N = 24) and a subset (N = 14) also completed post-treatment scans."
Small paired-imaging subset of the open trial.
PMID:41803077 SUPPORT Human Clinical
"Pre-treatment activation in response to food versus objects was not associated with changes in ARFID severity or remission post-treatment."
The baseline measure did not significantly predict clinical response.
PMID:41803077 SUPPORT Human Clinical
"There were no significant pre- to post-treatment changes in the aINS or the amygdala."
Negative regional results prevent generalized salience-network normalization claims.
+ 1 more reference
📈

Progression

1
Variable persistence and remission
Age: 9-23 years at baseline in the prospective cohort
In a prospective cohort of 100 participants with full or subthreshold ARFID, 44% retained their original diagnosis across both annual follow-ups. Outcome estimates depended on how subthreshold illness was classified. Follow-up combined structured interviews and chart review; the sample was predominantly White and was not a population prevalence sample. Three participants developed anorexia nervosa while retaining restrictive eating symptoms, emphasizing reassessment of weight/shape motivation over time.
Show evidence (2 references)
PMID:38718975 SUPPORT Human Clinical
"In the full sample (N = 100), 44% (n = 44) persisted in their original diagnosis across both follow-ups, while 12% (n = 12) achieved remission at Year 1 that was sustained through Year 2."
Uses the full-text longitudinal trajectory counts rather than converting the abstract wording of roughly half into an exact universal prognosis.
PMID:38718975 SUPPORT Human Clinical
"three participants (3%) experienced diagnostic shift to another the restricting type of AN (ANr) at Year 1 and retained ANr at Year 2."
Observed crossover in this cohort; not a lifetime risk estimate.
📊

Prevalence

2
Non-clinical samples of children and adolescents
Unknown 300.0–15500.0 per 100,000 >1 in 1,000
Range across heterogeneous non-clinical pediatric studies, 0.3%-15.5% (300-15,500 per 100,000); not a pooled prevalence or a confidence interval. Studies mixed diagnostic interviews and screening questionnaires. The lower estimate was six-month prevalence in Taiwanese schoolchildren, while the two highest estimates came from parent questionnaires that did not assess DSM-5 exclusion criteria.
Show evidence (2 references)
PMID:36527163 SUPPORT Human Clinical
"Studies from non-clinical samples reported ARFID prevalence estimates ranging from 0.3% to 15.5%."
Reported range across separate studies, not a pooled estimate; the lower endpoint must not be presented as the point prevalence.
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108140/ SUPPORT Human Clinical
"The two studies that reported the highest prevalence in community samples (i.e., 10.9% and 15.5%) used instruments that did not include items assessing the DSM‐5 exclusion criteria in the parent questionnaires."
The full-text methodological caveat prevents interpreting the upper screening estimates as confirmed diagnostic prevalence.
Canadian children and adolescents aged 5-18 presenting to pediatricians
Annual Incidence 2.02 per 100,000 1–9 per 100,000 per year
National active-surveillance estimate for cases reaching pediatric care in Canada; not the incidence of all ARFID in the community.
Show evidence (1 reference)
PMID:36527163 SUPPORT Human Clinical
"reported the incidence of ARFID in children and adolescents reaching clinical care to be 2.02 per 100,000 patients"
Systematic-review-cited national surveillance incidence estimate.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Avoidant Restrictive Food Intake Disorder:

Anorexia Nervosa MONDO:0005351
Overlapping Features Anorexia nervosa also involves restricted intake and low weight, but is driven by fear of weight gain and body-image disturbance — the motivation that ARFID lacks. A minority of ARFID cases cross over to anorexia nervosa.
Distinguishing Features
  • ARFID restriction occurs without drive for thinness, fear of weight gain, or body-image disturbance; anorexia nervosa is defined by exactly this weight/shape motivation.
Show evidence (1 reference)
PMID:38718975 SUPPORT Human Clinical
"half the participants persisted with their original diagnosis, and 3% of participants experienced a diagnostic shift to anorexia nervosa"
Prospective-course evidence supports anorexia nervosa as a distinct diagnosis with only a small ARFID-to-AN diagnostic crossover.
Pica MONDO:0001441
Overlapping Features Pica also involves abnormal eating without body-image disturbance, but is defined by ingestion of non-nutritive, non-food substances rather than by restriction/avoidance of normal food.
Distinguishing Features
  • ARFID is defined by restriction/avoidance of food intake; pica is defined by persistent ingestion of non-nutritive, non-food substances.
Show evidence (1 reference)
PMID:35674869 SUPPORT BACKGROUND Human Clinical
"Pica is defined by the American Psychiatric Association's Diagnostic and Statistical Manual, 5th edition (DSM 5) as the ongoing ingestion of materials with no nutritive or food value."
Supports the defining ingestion behavior that distinguishes pica from restriction or avoidance of ordinary food.
🔬

Clinical Trials

6
NCT04450771 NOT_APPLICABLE COMPLETED
Completed randomized comparison of family-based treatment and psychoeducational motivational therapy in underweight children with ARFID. Published results favor FBT-ARFID for weight gain, with no overall between-group difference in ARFID symptom improvement.
Show evidence (1 reference)
PMID:42019720 SUPPORT Human Clinical
"CLINICAL TRIAL REGISTRATION INFORMATION: Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. https://clinicaltrials.gov/study/NCT04450771."
Links the completed registered trial to its 2026 outcome publication.
NCT02963220 NOT_APPLICABLE COMPLETED
Completed single-group CBT-AR pilot with separate youth and adult outcome publications. The uncontrolled design evaluates feasibility and preliminary change; it does not establish comparative efficacy.
Show evidence (1 reference)
clinicaltrials:NCT02963220 SUPPORT Human Clinical
"The primary aim of this study is to pilot cognitive behavioral therapy (CBT-AR)for avoidant/restrictive food intake disorder (ARFID) in one study for children and adolescents (ages 10-17 years) and one study for adults (ages 18-65 years)."
Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
NCT03778216 NOT_APPLICABLE COMPLETED
Completed feasibility study of family-based treatment compared with usual care using a randomized crossover design.
Show evidence (1 reference)
clinicaltrials:NCT03778216 SUPPORT Human Clinical
"This randomized controlled crossover trial (RCCT) will test the feasibility and acceptability of a novel intervention, Family-Based Treatment of Avoidant/Restrictive Food Intake Disorder (FBT-ARFID) for patients ages 5-12 years old."
Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
NCT05954728 NOT_APPLICABLE COMPLETED
Randomized comparison of CBT-AR with nutrition counseling, studying cognitive and neural mechanisms in youth.
Show evidence (1 reference)
clinicaltrials:NCT05954728 SUPPORT Human Clinical
"This study is a randomized controlledlinical trial, assessing the efficacy of cognitive- behavioral therapy (CBT-AR) and nutrition counseling for avoidant/restrictive food intake disorder (ARFID) for children and adolescents (ages 10-18 years)."
Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
NCT06110806 NOT_APPLICABLE TERMINATED
Single-group feasibility study of family-based mindfulness and interoceptive exposure. The registry records early termination; the planned primary acceptability outcome was not collected.
Show evidence (2 references)
clinicaltrials:NCT06110806 SUPPORT Human Clinical
"This project aims to establish the feasibility and acceptability of a comprehensive mind and body intervention; specifically a mindfulness-based interoceptive exposure (MBIE) for families of youth diagnosed with avoidant/restrictive food intake disorder (ARFID)."
Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
url:https://clinicaltrials.gov/api/v2/studies/NCT06110806 SUPPORT Human Clinical
"Data not collected because 6 month visit not completed due to early termination of study."
ClinicalTrials.gov NCT06110806, Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Posted primary-outcome record documents the missing six-month assessment after early termination.
NCT06420232 NOT_APPLICABLE TERMINATED
Related feeding-anxiety pilot of a weighted blanket before meals. Eligibility required feeding challenges and caregiver-reported food anxiety, not a confirmed ARFID diagnosis. The study was terminated and does not establish an ARFID treatment.
Show evidence (1 reference)
clinicaltrials:NCT06420232 SUPPORT Human Clinical
"This small experimental pilot study addresses the knowledge gap related to the use of weighted blankets for children with anxiety related to food and eating."
Registry summary identifies the broader feeding-anxiety population, rather than an ARFID-specific efficacy trial.
{ }

Source YAML

click to show 
name: Avoidant Restrictive Food Intake Disorder
creation_date: '2026-07-29T00:00:00Z'
category: Psychiatric
description: 'Avoidant/restrictive food intake disorder (ARFID) is a feeding and eating disorder characterized by persistent failure to meet nutritional and/or energy needs due to avoidance or restriction of food intake, in the absence of body-image disturbance or drive for thinness. Restriction is driven by one or more of three DSM-5 presentations: sensory sensitivity to the taste, texture, smell, or appearance of food; an apparent lack of interest in eating or low appetite; and fear of aversive consequences of eating (such as choking or vomiting). The absence of weight- and shape-related motivation is the key contrast with anorexia nervosa. ARFID was introduced in DSM-5 (2013), replacing and expanding the former "feeding disorder of infancy or early childhood," and shows strong neurodevelopmental (autism, ADHD) and anxiety-disorder comorbidity.'
disease_term:
  preferred_term: avoidant/restrictive food intake disorder
  term:
    id: MONDO:7770002
    label: avoidant/restrictive food intake disorder
parents:
- Eating Disorder
- Mental Health Disorder
pathophysiology:
- name: Multifactorial Genetic and Environmental Liability
  description: 'A Swedish twin study estimated substantial genetic liability for a broad childhood ARFID phenotype defined from parent reports and health registers. Its best-fitting model estimated heritability of 0.79 (95% CI 0.70-0.85) and a nonshared environmental contribution of 0.21 (95% CI 0.15-0.30). Ascertainment emphasized sensory restriction, did not directly assess every diagnostic exclusion, and included a sibling-contrast parameter. These estimates do not identify causal genes or establish equal heritability across ages and ARFID presentations. Common-variant studies also support genetic contributions to avoidant/restrictive eating, but use different ascertainment: ARFI traits in a Norwegian population cohort and an algorithm-derived risk score in an autism cohort. Neither establishes a single causal pathway or a diagnostic genetic test for ARFID.'
  biological_scale: ORGANISM
  downstream:
  - target: Sensory Sensitivity and Food Selectivity
    description: Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
  - target: Low Appetite and Lack of Interest in Eating
    description: Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
  - target: Fear of Aversive Consequences of Eating
    description: Conceptual placement of shared liability upstream of this presentation; the twin study did not estimate presentation-specific genetic effects.
  evidence:
  - reference: PMID:36723946
    reference_title: Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The heritability of ARFID was 0.79 (95% CI, 0.70-0.85), with significant contributions from nonshared environmental factors (0.21; 95% CI, 0.15-0.30).
    explanation: Estimate for a broadly defined phenotype in Swedish twins aged 6-12 years; this is population-level variance partitioning, not individual risk or molecular evidence of a polygenic mechanism.
  - reference: PMID:41284261
    reference_title: Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SNV heritability (SNV-h2) estimates on the liability scale ranged from 8% to 16%
    explanation: Common-variant estimates for parent-reported restrictive-eating phenotypes; these are not directly comparable with the Swedish twin heritability estimate.
  - reference: PMID:34177659
    reference_title: Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'the proband ARFID Score was estimated to have significant SNP h2 of 0.45 (95% CI: 0.13–0.76)'
    explanation: Estimate for an algorithm-derived score in autistic probands, with a wide interval; it is not heritability of clinically diagnosed ARFID in the general population.
- name: Sensory Sensitivity and Food Selectivity
  description: Sensory-based avoidance of food limits accepted variety. A fasting visual-food-cue fMRI study found higher anterior cingulate and sensory association cortex activation in the sensory-sensitivity group, but no greater insula activation than healthy controls. These are brain-region associations from a passive viewing task, not evidence of taste-receptor-cell dysfunction or a proven causal sensory circuit. Full and subthreshold ARFID were included, and phenotype groups overlapped.
  biological_scale: ORGANISM
  downstream:
  - target: Restriction and Avoidance of Food Intake
    description: Sensory aversion is modeled as one upstream driver of the core restriction/avoidance behavior.
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with ARFID may limit food variety and intake due to avoidance based on the sensory characteristics of the food
    explanation: Narrative-review evidence supports sensory-based avoidance as one of the core drivers of restricted intake in ARFID.
  - reference: PMID:39964683
    reference_title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The ARFID-sensory sensitivity group did not show greater insula activation vs HC but showed greater activation of the ACC
    explanation: fMRI food-cue evidence supports a distinct cortical sensory-processing activation pattern in the sensory-sensitivity ARFID phenotype.
- name: Low Appetite and Lack of Interest in Eating
  description: Low interest in eating, low hunger and early satiation can limit intake. Within the lack-of-interest phenotype group, greater symptom severity correlated with lower right hypothalamus activation during a fasting visual-food-cue task. The group did not show lower hypothalamus activation than healthy controls overall. This cross-sectional association does not establish hypothalamic dysfunction as the cause of restriction or identify the responsible endocrine cell type. In a separate self-report study, ARFID severity correlated with lower anticipatory pleasure even after food items were removed. This broader reward association and the contribution of depressive symptoms do not establish a food-specific reward defect or its causal direction.
  biological_scale: ORGANISM
  downstream:
  - target: Restriction and Avoidance of Food Intake
    description: Low appetite / lack of interest is modeled as a second upstream driver of restricted intake.
  - target: Poor Appetite
    description: The low-interest/appetite presentation has poor appetite as a clinical manifestation.
  evidence:
  - reference: PMID:34423319
    reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: including sensory sensitivity, lack of interest in eating or food, and fear of aversive consequences.
    explanation: The structured interview assesses lack of interest as one presentation; ARFID as a whole is not limited to low appetite.
  - reference: PMID:39964683
    reference_title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: greater lack of interest was associated with lower hypothalamus activation in the ARFID-lack of interest group
    explanation: Within-group association between symptom severity and lower right hypothalamus response; the lack-of-interest group did not differ from controls overall.
  - reference: PMID:37950288
    reference_title: Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: greater endorsement of the lack of interest in food profile was related to lower anticipatory pleasure
    explanation: Exploratory association with self-reported anticipatory pleasure, including analyses without food items. The full-scale profile association was not significant after covariate adjustment; this is not proof of a food-specific reward mechanism.
  - reference: PMID:37950288
    reference_title: Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The ARFID group reported significantly lower anticipatory and consummatory pleasure compared to HCs, but these differences were no longer significant after controlling for depression
    explanation: The case-control difference attenuated with adjustment for depression and BMI. Neither this negative result nor removal of food questions proves the absence of generalized anhedonia.
  - reference: PMID:39964683
    reference_title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Contrary to hypotheses, at the ROI level, the ARFID–lack of interest group did not show lower hypothalamus activation vs HC while viewing food (vs nonfood) images.
    explanation: The within-group severity correlation must not be represented as a case-control hypothalamic deficit.
  - reference: PMID:37950288
    reference_title: Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Within the ARFID sample, individuals with more severe ARFID reported less anticipatory pleasure, even after removing questions about enjoyment of food.
    explanation: The severity association extends beyond food-related questionnaire items; the cross-sectional study cannot resolve whether altered pleasure precedes or follows ARFID.
  notes: Appetite-hormone studies provide a possible biological correlate, summarized under biochemical findings. They measure circulating hormones, not pathology of enteroendocrine cells, and do not establish hormone dysregulation as an initiating cause. Several neuroimaging, pleasure, endocrine and course papers draw from the same NIMH-funded ARFID cohort and should not be treated as independent replications.
- name: Fear of Aversive Consequences of Eating
  description: Fear of choking, vomiting, pain or another aversive consequence can maintain food avoidance. In a fasting visual-food-cue study, participants with the fear phenotype showed greater left-amygdala activation than healthy controls at the region-of-interest level. Fear severity did not correlate significantly with amygdala activation, and the phenotype contrast was not significant in the whole-brain analysis. Findings are associations and do not establish a specific neuronal subtype or prove that a prior adverse event caused the observed response.
  biological_scale: ORGANISM
  downstream:
  - target: Restriction and Avoidance of Food Intake
    description: Fear of aversive consequences is modeled as a third upstream driver of restricted intake.
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: related to any adverse consequences of eating
    explanation: Narrative-review evidence identifies fear of adverse consequences of eating as a distinct driver of avoidance in ARFID.
  - reference: PMID:39964683
    reference_title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The ARFID-fear group showed greater amygdala activation vs HC
    explanation: fMRI evidence supports fear-circuit (amygdala) hyperactivation in the fear-of-aversive-consequences ARFID phenotype.
  - reference: PMID:40568462
    reference_title: 'Avoidant/Restrictive Food Intake Disorder in Adult Patients with Gastrointestinal Diseases: A Concept Analysis Using Evolutionary Approach.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Antecedents include gastrointestinal diseases and symptoms, traumatic events and experiences, dietary adversities history, and nutritional misconceptions.
    explanation: Concept analysis of heterogeneous adult GI studies identifies candidate antecedents. The authors state that causal direction between GI disease and ARFID remains unresolved; medically necessary restriction alone does not establish ARFID.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:39275348
    reference_title: 'Development and Management of Avoidant/Restrictive Food Intake Disorder and Food Neophobia in Pediatric Patients with Food Allergy: A Comprehensive Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the fear of allergic reactions exacerbates avoidance and restrictive patterns
    explanation: Review evidence in food-allergic children supports fear of an allergic reaction as a precipitant that amplifies avoidant/restrictive eating.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:39964683
    reference_title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, within the ARFID-fear group, the PARDI fear of aversive consequences subscale was not significantly associated with amgydala activation.  # codespell:ignore amgydala
    explanation: Preserves the negative symptom-severity result; the source misspells amygdala.
  - reference: PMID:40568462
    reference_title: 'Avoidant/Restrictive Food Intake Disorder in Adult Patients with Gastrointestinal Diseases: A Concept Analysis Using Evolutionary Approach.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At present, there is insufficient research to establish a clear causal relationship between the two.
    explanation: The proposed bidirectional GI-ARFID relationship is not established as causal.
    quote_role: REVIEW_SYNTHESIS
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These behaviors are not limited to the avoidance of allergens but may extend to normally tolerated foods.
    explanation: 'Full text of PMID:39275348 (Development and Management of Avoidant/Restrictive Food Intake Disorder and Food Neophobia in Pediatric Patients with Food Allergy: A Comprehensive Review.) retrieved through PMC/BioC. The review distinguishes generalized avoidance from avoidance of confirmed allergens; it does not justify exposure to an allergen as ARFID treatment.'
    quote_role: REVIEW_SYNTHESIS
  notes: Food-allergy-related anxiety can extend avoidance to tolerated foods. Clinically necessary allergen avoidance is not itself ARFID; additional restriction and impairment must exceed what the medical condition explains. Care integrates appropriate allergy management with nutritional and behavioral support.
- name: Neurodevelopmental and Anxiety-Disorder Comorbidity
  description: Autism spectrum disorder, ADHD and anxiety disorders can co-occur with ARFID. Autism was more frequent in sensory and combined presentations, while anxiety was more frequent in the fear presentation in a secondary-care surveillance cohort. These associations provide clinical context, not proof that a comorbid diagnosis causes a particular ARFID presentation.
  biological_scale: ORGANISM
  downstream:
  - target: Sensory Sensitivity and Food Selectivity
    description: Proposed modifying context; observational comorbidity does not establish causal direction.
  - target: Fear of Aversive Consequences of Eating
    description: Proposed modifying context; observational comorbidity does not establish causal direction.
  evidence:
  - reference: PMID:36527163
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%).
    explanation: Systematic-review evidence supports high anxiety-disorder and autism comorbidity in children and adolescents with ARFID.
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Combined subtype and the Sensory subtype had significantly more ASD than the other two classes
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Presentation-associated comorbidity in clinician-reported secondary-care cases; applicability outside this ascertainment is uncertain.'
- name: Restriction and Avoidance of Food Intake
  description: 'The convergent core behavior: persistent avoidance or restriction of food intake reached by any of the three drivers, critically without the drive for thinness, fear of weight gain, or body-image disturbance that defines anorexia nervosa. This absence of weight/shape motivation is the defining contrast with anorexia nervosa. The three drivers are dimensional and frequently co-occur rather than being mutually exclusive subtypes: an empirical latent-class analysis of 319 children/adolescents found a mixed (combined) presentation to be the single most common class.'
  biological_scale: ORGANISM
  downstream:
  - target: Failure to Meet Nutritional and Energy Needs
    description: Restricted/avoidant intake is modeled upstream of nutritional and energy failure.
  - target: Restrictive Eating
    description: The pathophysiologic restriction behavior maps to the clinical restrictive-eating phenotype.
  - target: Feeding Difficulties
    description: Restricted range and amount of food manifest as feeding difficulties.
  - target: Psychosocial Impairment Related to Eating
    description: Avoidance of food and eating situations can impair social participation and family functioning.
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: without the intention of losing weight and concerns of body image
    explanation: Narrative-review evidence supports the defining feature that ARFID restriction occurs without weight-loss intent or body-image concern, distinguishing it from anorexia nervosa.
  - reference: PMID:36723946
    reference_title: Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: with fear of weight gain as an exclusion
    explanation: The twin-study ARFID phenotype definition explicitly excludes fear of weight gain, reinforcing the absence of weight/shape motivation.
  - reference: PMID:38333539
    reference_title: 'Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LCA revealed four distinct classes which were labelled as Fear subtype, Lack of Interest subtype, Sensory subtype, and Combined subtype.
    explanation: National-surveillance latent-class analysis empirically recovers the three DSM-5 drivers plus a combined class, supporting the convergent multi-driver model of ARFID restriction.
  - reference: PMID:38333539
    reference_title: 'Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Combined Subtype, a mixed presentation was the most common.
    explanation: The most common empirically identified class was a mixed/combined presentation, indicating the three drivers are overlapping dimensions rather than mutually exclusive subtypes.
  notes: The latent-class study used clinician-reported secondary-care cases in the UK and Republic of Ireland, without independent PARDI confirmation. Its combined class chiefly mixed sensory sensitivity and lack of interest; the observed proportions are not population-wide subtype prevalence.
- name: Failure to Meet Nutritional and Energy Needs
  description: Inadequate energy or nutrient intake can cause weight loss, growth faltering and nutrient deficiencies. Severe or prolonged undernutrition can impair cardiovascular, gastrointestinal, skeletal and pubertal function. These consequences vary with the degree and pattern of restriction; ARFID can also present through psychosocial impairment without low weight.
  biological_scale: ORGANISM
  downstream:
  - target: Weight Loss
    description: Nutritional/energy failure manifests as weight loss.
  - target: Failure to Thrive
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Anemia
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Bradycardia
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Constipation
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Delayed Puberty
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Amenorrhea
    description: Nutritional compromise can contribute to this clinical consequence.
  - target: Reduced Bone Mineral Density
    description: Nutritional compromise can contribute to this clinical consequence.
  evidence:
  - reference: PMID:36723946
    reference_title: Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an extremely limited range and/or amount of food eaten, resulting in the persistent failure to meet nutritional and/or energy needs
    explanation: Twin-study evidence supports restricted intake producing persistent failure to meet nutritional and energy needs.
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These symptoms are attributed to deficiencies in macronutrients and micronutrients
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Clinical review connects the severe physical manifestations with inadequate nutrient intake.'
- name: Psychosocial Impairment Related to Eating
  biological_scale: ORGANISM
  description: Restricted eating can interfere with school, peer and family activities involving food. Marked psychosocial interference can satisfy the impairment criterion even without low weight or another nutritional consequence.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Selectivity and extreme food avoidance can hinder a child’s experiences in social settings, including interactions related to eating at school or with peers.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Psychosocial impairment is a direct consequence of restrictive eating, not necessarily a consequence of undernutrition.'
phenotypes:
- name: Restrictive Eating
  description: 'The core behavioral phenotype: persistent avoidance or restriction of food intake, limiting the range and/or amount of food eaten.'
  phenotype_term:
    preferred_term: Restrictive eating
    term:
      id: HP:0020302
      label: Restrictive eating
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Individuals with ARFID may limit food variety and intake due to avoidance based on the sensory characteristics of the food
    explanation: Narrative-review evidence supports restriction/limitation of food variety and intake as the defining ARFID phenotype.
- name: Poor Appetite
  description: An apparent lack of interest in eating and low appetite is a core presentation of ARFID, present especially in the inappetence phenotype.
  phenotype_term:
    preferred_term: Poor appetite
    term:
      id: HP:0004396
      label: Poor appetite
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Lack of Interest subtype was characterised by high probabilities of lack of appetite (0.85) and lack of interest in eating or food (1.0)
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Poor appetite is characteristic of this presentation, not universal across ARFID.'
- name: Feeding Difficulties
  description: Restricted range and amount of food eaten manifests clinically as feeding difficulty, a core feature across ARFID presentations.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:36723946
    reference_title: Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an extremely limited range and/or amount of food eaten
    explanation: Twin-study characterization of ARFID as extremely limited range/amount of food eaten supports feeding difficulties as a phenotype.
- name: Weight Loss
  description: Loss of body weight can result from restricted energy intake; this is distinct from low weight without documented loss and from growth faltering in children.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:38753906
    reference_title: Avoidant Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARFID is characterized by significant limitations in food intake leading to malnutrition, weight loss, or nutritional deficiency
    explanation: Clinical overview explicitly supports weight loss rather than equating all low weight with weight loss.
- name: Anxiety
  description: Anxiety is a highly prevalent comorbidity in ARFID, most tightly linked to the fear-of-aversive-consequences presentation.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:36527163
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%)
    explanation: Systematic-review evidence supports anxiety disorders as a common ARFID comorbidity.
  notes: Recorded as a co-occurring clinical feature; the evidence does not establish that ARFID causes this finding.
- name: Autistic Behavior
  description: Autism spectrum disorder is markedly over-represented among individuals with ARFID and is a major comorbidity context, particularly for the sensory-sensitivity presentation.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:36527163
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Psychiatric comorbidity was common, especially anxiety disorders (9.1%-72%) and autism spectrum disorder (8.2%-54.75%).
    explanation: Systematic-review evidence supports autism spectrum disorder as a common ARFID comorbidity.
  notes: Recorded as a co-occurring clinical feature; the evidence does not establish that ARFID causes this finding.
- name: Failure to Thrive
  description: Children may fail to achieve expected growth when energy intake is inadequate.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: failure to achieve expected and adequate growth or delayed growth
    explanation: Growth faltering is a diagnostic consequence distinct from weight loss.
- name: Anemia
  description: Restricted dietary variety can produce nutrient deficiency and anemia.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis of ARFID is made when the individual fails to meet appropriate nutritional requirements (such as anemia and vitamin deficiency)
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. The clinical review identifies anemia among nutritional consequences.'
- name: Bradycardia
  description: Bradycardia may occur in severe malnutrition associated with ARFID.
  phenotype_term:
    preferred_term: Bradycardia
    term:
      id: HP:0001662
      label: Bradycardia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: electrolyte abnormalities (e.g., hypokalemia), dry skin, lanugo, alopecia, bradycardia, orthostatic postural tachycardia, hypotension, and a sunken abdomen.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. These findings are described in severe ARFID-related malnutrition, not as universal features.'
- name: Constipation
  description: Constipation can accompany nutritional restriction in severe ARFID.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: fatigue, lethargy, difficulty concentrating, memory deficits, presyncope, constipation, hypersensitivity to cold, hypothermia
    explanation: Clinical review lists constipation among manifestations of severe malnutrition.
- name: Delayed Puberty
  description: Pubertal delay can accompany prolonged nutritional compromise.
  phenotype_term:
    preferred_term: Delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: female patients with ARFID may experience pubertal delay before the onset of menstruation.
    explanation: The cited clinical description concerns females; no frequency or cross-sex generalization is assigned.
- name: Amenorrhea
  description: Primary or secondary amenorrhea may occur with nutritional compromise and low body weight.
  phenotype_term:
    preferred_term: Amenorrhea
    term:
      id: HP:0000141
      label: Amenorrhea
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary amenorrhea may occur, and in postmenarcheal patients, secondary amenorrhea may result from low body weight.
    explanation: The review distinguishes failure to start menstruating from cessation after menarche.
- name: Reduced Bone Mineral Density
  description: Reduced bone mineral density may accompany nutritional compromise and menstrual or pubertal abnormalities.
  phenotype_term:
    preferred_term: Reduced bone mineral density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary amenorrhea may occur, and in postmenarcheal patients, secondary amenorrhea may result from low body weight. These findings are associated with lower bone mineral density.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. The adjacent text describes delayed puberty and amenorrhea; this does not establish osteoporosis in every patient.'
genetic:
- name: ADCY3 association with avoidant/restrictive food-intake traits
  gene_term:
    preferred_term: ADCY3
    term:
      id: hgnc:234
      label: ADCY3
  relationship_type: UNKNOWN
  association: Genome-wide association with an ARFI-clinical trait definition; relationship to formally diagnosed ARFID remains unresolved
  notes: The Norwegian MoBa study identified rs11676272 and a gene-based ADCY3 association for mother-reported avoidant/restrictive eating with clinical indicators at age 3 or 8. Its definition did not assess all ARFID diagnostic requirements, including fear of aversive consequences, psychosocial impairment and several exclusion criteria. Ancestry, ascertainment, replication and causal mechanism limit translation to ARFID; no Mendelian inheritance or molecular loss/gain of function is inferred.
  evidence:
  - reference: PMID:41284261
    reference_title: Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One gene, ADCY3, located on chromosome 2, was associated with ARFI-clinical at 3 or 8 years
    explanation: Gene-based association after multiple-testing correction; the phenotype is explicitly narrower in diagnostic ascertainment than ARFID.
  - reference: PMID:41284261
    reference_title: Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Therefore, phenotypes should not be interpreted as ARFID diagnoses, but as ARFID traits, accompanied by additional co-occurring indicators of clinical significance for ARFI-clinical.
    explanation: Authors explicitly limit the diagnostic interpretation of the association.
  - reference: PMID:41284261
    reference_title: Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Future studies are needed to replicate associations between individual genetic variants and avoidant/restrictive eating and investigate the biological mechanisms underlying these associations.
    explanation: No specific ARFID causal mechanism or clinically validated genetic test is established.
- name: Locus near ZSWIM6 associated with an ARFID risk score in autism
  gene_term:
    preferred_term: ZSWIM6
    term:
      id: hgnc:29316
      label: ZSWIM6
  relationship_type: UNKNOWN
  association: Nearest-gene annotation of a genome-wide signal for an algorithm-derived ARFID score in autistic probands
  notes: The SPARK analysis found rs13177031 near ZSWIM6 using an eating-behavior score trained on reported ARFID diagnoses. Genotyped probands were of European ancestry; the score was not an independently confirmed ARFID diagnosis. Physical proximity does not establish ZSWIM6 as the regulatory target or causal gene. Other reported loci did not reach genome-wide significance and are not treated as established associations.
  evidence:
  - reference: PMID:34177659
    reference_title: Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One SNP on chromosome 5, rs13177031 (p = 1.6 × 10−8), reached genome wide significance
    explanation: Genome-wide association with the proband risk score, not a Mendelian disease variant.
  - reference: PMID:34177659
    reference_title: Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genome-wide association revealed a single hit near ZSWIM6, a gene previously implicated in neurodevelopmental conditions.
    explanation: Nearest-gene annotation only; neither variant-to-gene regulation nor a causal ARFID role was demonstrated.
  - reference: PMID:34177659
    reference_title: Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: it was not well-situated to conclusively distinguish ARFID risk factors from those of other eating disorders.
    explanation: The study acknowledges diagnostic specificity limitations of self- and parent-reported phenotyping.
prevalence:
- population: Non-clinical samples of children and adolescents
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 300.0
  rate_high: 15500.0
  notes: Range across heterogeneous non-clinical pediatric studies, 0.3%-15.5% (300-15,500 per 100,000); not a pooled prevalence or a confidence interval. Studies mixed diagnostic interviews and screening questionnaires. The lower estimate was six-month prevalence in Taiwanese schoolchildren, while the two highest estimates came from parent questionnaires that did not assess DSM-5 exclusion criteria.
  evidence:
  - reference: PMID:36527163
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Studies from non-clinical samples reported ARFID prevalence estimates ranging from 0.3% to 15.5%.
    explanation: Reported range across separate studies, not a pooled estimate; the lower endpoint must not be presented as the point prevalence.
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108140/
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The two studies that reported the highest prevalence in community samples (i.e., 10.9% and 15.5%) used instruments that did not include items assessing the DSM‐5 exclusion criteria in the parent questionnaires.
    explanation: The full-text methodological caveat prevents interpreting the upper screening estimates as confirmed diagnostic prevalence.
  measure_type: UNKNOWN
- population: Canadian children and adolescents aged 5-18 presenting to pediatricians
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.02
  notes: National active-surveillance estimate for cases reaching pediatric care in Canada; not the incidence of all ARFID in the community.
  evidence:
  - reference: PMID:36527163
    reference_title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: reported the incidence of ARFID in children and adolescents reaching clinical care to be 2.02 per 100,000 patients
    explanation: Systematic-review-cited national surveillance incidence estimate.
treatments:
- name: Cognitive-Behavioral Therapy for ARFID (CBT-AR)
  description: CBT-AR combines regular eating, nutritional planning, presentation-specific exposure and relapse prevention. Sensory sensitivity is addressed through repeated food tasting, fear through graded exposure, and lack of interest through interoceptive exposure. Small uncontrolled outpatient studies in youth and adults reported lower ARFID severity and greater food variety; these studies establish feasibility and preliminary benefit, not comparative efficacy.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: cognitive behavior therapy for ARFID (CBT-AR)
    term:
      id: NCIT:C64345
      label: Cognitive Behavior Therapy
  evidence:
  - reference: PMID:34423319
    reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures.
    explanation: The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
  - reference: PMID:32776570
    reference_title: 'Cognitive-behavioral therapy for avoidant/restrictive food intake disorder: Feasibility, acceptability, and proof-of-concept for children and adolescents.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 25 eligible individuals, 20 initiated treatment, including 17 completers and 3 dropouts.
    explanation: Uncontrolled feasibility study in medically stable youth aged 10-17; most received family-supported CBT-AR with medical monitoring.
  - reference: PMID:32776570
    reference_title: 'Cognitive-behavioral therapy for avoidant/restrictive food intake disorder: Feasibility, acceptability, and proof-of-concept for children and adolescents.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARFID severity scores (on the Pica, ARFID, and Rumination Disorder Interview) significantly decreased per both patient and parent report. Patients incorporated a mean of 16.7 (SD = 12.1) new foods from pre- to post-treatment.
    explanation: Within-person improvements in the youth pilot; the absence of a control group prevents attribution of improvement specifically to CBT-AR.
  - reference: PMID:34423319
    reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of 18 eligible adults offered CBT-AR, 15 chose to participate and 14 completed treatment.
    explanation: Adult open trial, predominantly individual treatment; small, demographically homogeneous sample limits generalizability.
  - reference: PMID:34423319
    reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: At post-treatment, 47% of patients no longer met criteria for ARFID.
    explanation: Diagnostic remission in the adult intent-to-treat sample; not a randomized comparison or evidence of long-term durability.
  - reference: PMID:34423319
    reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Second, with no control group we cannot rule out alternative rival hypotheses for the observed improvements (e.g., therapist attention, passage of time).
    explanation: Authors explicitly identify the causal limitation of the adult open trial.
  target_mechanisms:
  - target: Sensory Sensitivity and Food Selectivity
    description: Repeated tasting and sensory exposure address food selectivity.
    evidence:
    - reference: PMID:34423319
      reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures.
      explanation: The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
  - target: Fear of Aversive Consequences of Eating
    description: Graded exposure addresses feared consequences and avoidance.
    evidence:
    - reference: PMID:34423319
      reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures.
      explanation: The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
  - target: Low Appetite and Lack of Interest in Eating
    description: Interoceptive exposure addresses the low-interest presentation.
    evidence:
    - reference: PMID:34423319
      reference_title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with sensory sensitivity taste five novel foods per session; patients with fear of aversive consequences work through a fear and avoidance hierarchy; and patients with lack of interest practice interoceptive exposures.
      explanation: The treatment manual selects exposure modules according to the maintaining presentation; more than one module can be used.
- name: Family-Based Treatment (FBT-ARFID)
  description: Family-based treatment adapted for ARFID trains caregivers to change restrictive eating, followed by return to age-appropriate self-management. A randomized trial of 98 medically stable, underweight children aged 6-12 compared 14 telehealth sessions over four months with individual psychoeducational motivational therapy. FBT-ARFID produced greater weight gain, but overall ARFID symptom severity improved similarly in both groups. This trial does not establish efficacy across adult or non-underweight populations.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Family Therapy
    term:
      id: NCIT:C93347
      label: Family Therapy
  evidence:
  - reference: PMID:42019720
    reference_title: 'Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A total of 98 children with ARFID were randomized to 14 sessions of telehealth FBT-ARFID or PMT conducted over 4 months.
    explanation: Randomized active-comparator trial in underweight children aged 6-12; assessments were masked, but weight, height and behavioral outcomes relied on parent reports.
  - reference: PMID:42019720
    reference_title: 'Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: FBT-ARFID was superior to PMT at EOT in promoting increased %EBW. There were no differences between groups regarding improvements in overall severity of ARFID symptoms or other related ARFID symptoms
    explanation: Preserves the distinction between the positive primary weight outcome and the absence of overall symptom superiority. Baseline-severity moderation was exploratory.
- name: Nutritional Rehabilitation and Enteral Feeding
  description: Individualized dietetic rehabilitation restores adequate energy, fluids and micronutrients, initially using accepted foods and oral supplements when needed. Enteral support may be necessary for severe restriction or malnutrition and is reassessed as oral intake improves. Refeeding requires monitoring for electrolyte abnormalities and clinical instability.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: nutritional rehabilitation with enteral tube feeding
    term:
      id: NCIT:C67022
      label: Nutritional Intervention
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This can be achieved through the consumption of foods that are more readily accepted by the individual, as well as the prescription of nutritional supplements via oral or enteral nutrition.
    explanation: Supports accepted foods and individualized supplementation during nutritional rehabilitation.
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: close monitoring for electrolyte abnormalities, which may arise from refeeding syndrome—a serious and potentially fatal complication—is essential
    explanation: Supports monitoring during nutritional rehabilitation because refeeding can cause dangerous electrolyte abnormalities.
  target_mechanisms:
  - target: Failure to Meet Nutritional and Energy Needs
    description: Accepted foods and oral or enteral supplementation restore nutritional intake.
    evidence:
    - reference: PMID:38849953
      reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This can be achieved through the consumption of foods that are more readily accepted by the individual, as well as the prescription of nutritional supplements via oral or enteral nutrition.
      explanation: Supports accepted foods and individualized supplementation during nutritional rehabilitation.
- name: Adjunctive Off-Label Pharmacotherapy
  description: Medication is used selectively alongside behavioral and nutritional treatment to address appetite, nausea, anxiety or psychiatric comorbidity. Mirtazapine has case-based and retrospective inpatient evidence. Olanzapine, buspirone, fluoxetine and cyproheptadine have been described in small reports or combined-treatment series, which cannot isolate drug effects. No ARFID-specific medication is established by these studies.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mirtazapine
      term:
        id: CHEBI:6950
        label: mirtazapine
  evidence:
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There is currently no psychotropic medication for treatment of ARFID approved by the U.S. Food and Drug Administration.
    explanation: The 2024 review reports no FDA-approved ARFID pharmacotherapy; the cited medication evidence concerns off-label use.
  - reference: PMID:38849953
    reference_title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: reported the use of mirtazapine to enhance appetite and facilitate weight gain while reducing nausea and vomiting
    explanation: Narrative-review evidence supports off-label mirtazapine as an appetite-stimulating agent used in ARFID.
  - reference: PMID:40265508
    reference_title: Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hospital records from 87 children and adolescents with ARFID treated in an inpatient medical stabilization program were analyzed.
    explanation: Retrospective inpatient study; 38 patients received mirtazapine. Prescribing was not randomized, concurrent treatment was intensive, and systematic adverse-effect assessment was unavailable.
  - reference: PMID:40265508
    reference_title: Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The results of this retrospective chart review suggest that treatment with mirtazapine is associated with reduced length of inpatient stay and total NG tube feeding days throughout a patient's stay.
    explanation: Association with shorter hospitalization and fewer total tube-feeding days; discharge BMI change and the proportion of hospitalization spent on tube feeding did not differ. This does not prove drug efficacy.
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The treatment approach included family therapy, cognitive-behavioural therapy, medical monitoring, and pharmacological treatment with olanzapine, fluoxetine, and cyproheptadine
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Small combined-treatment series summarized by the review; the individual medication contributions cannot be separated.'
differential_diagnoses:
- name: Anorexia Nervosa
  description: Anorexia nervosa also involves restricted intake and low weight, but is driven by fear of weight gain and body-image disturbance — the motivation that ARFID lacks. A minority of ARFID cases cross over to anorexia nervosa.
  distinguishing_features:
  - ARFID restriction occurs without drive for thinness, fear of weight gain, or body-image disturbance; anorexia nervosa is defined by exactly this weight/shape motivation.
  disease_term:
    preferred_term: anorexia nervosa
    term:
      id: MONDO:0005351
      label: anorexia nervosa
  evidence:
  - reference: PMID:38718975
    reference_title: Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: half the participants persisted with their original diagnosis, and 3% of participants experienced a diagnostic shift to anorexia nervosa
    explanation: Prospective-course evidence supports anorexia nervosa as a distinct diagnosis with only a small ARFID-to-AN diagnostic crossover.
- name: Pica
  description: Pica also involves abnormal eating without body-image disturbance, but is defined by ingestion of non-nutritive, non-food substances rather than by restriction/avoidance of normal food.
  distinguishing_features:
  - ARFID is defined by restriction/avoidance of food intake; pica is defined by persistent ingestion of non-nutritive, non-food substances.
  disease_term:
    preferred_term: pica disease
    term:
      id: MONDO:0001441
      label: pica disease
  evidence:
  - reference: PMID:35674869
    reference_title: The Neurology and Psychopathology of Pica.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: Pica is defined by the American Psychiatric Association's Diagnostic and Statistical Manual, 5th edition (DSM 5) as the ongoing ingestion of materials with no nutritive or food value.
    explanation: Supports the defining ingestion behavior that distinguishes pica from restriction or avoidance of ordinary food.
references:
- reference: PMID:38849953
  title: 'Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.'
  findings: []
- reference: PMID:36723946
  title: Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
  findings: []
- reference: PMID:39964683
  title: Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
  findings: []
- reference: PMID:38718975
  title: Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
  findings: []
- reference: PMID:39623765
  title: 'Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.'
  findings: []
- reference: PMID:36527163
  title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
  findings: []
- reference: PMID:37990202
  title: 'ARFID Genes and Environment (ARFID-GEN): study protocol.'
  findings: []
- reference: PMID:38333539
  title: 'Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.'
  findings: []
- reference: PMID:37950288
  title: Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder.
  findings: []
- reference: PMID:40568462
  title: 'Avoidant/Restrictive Food Intake Disorder in Adult Patients with Gastrointestinal Diseases: A Concept Analysis Using Evolutionary Approach.'
  findings: []
- reference: PMID:39275348
  title: 'Development and Management of Avoidant/Restrictive Food Intake Disorder and Food Neophobia in Pediatric Patients with Food Allergy: A Comprehensive Review.'
  findings: []
- reference: PMID:42019720
  title: 'Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.'
  findings: []
- reference: PMID:38753906
  title: Avoidant Restrictive Food Intake Disorder.
  findings: []
  tags:
  - StatPearls
- reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
  title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
  findings: []
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108140/
  title: What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature - PMC
  findings: []
- reference: PMID:35830620
  title: Elevated Fasting Satiety-Promoting Cholecystokinin (CCK) in Avoidant/Restrictive Food Intake Disorder Compared to Healthy Controls.
  findings: []
- reference: PMID:42159358
  title: Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
  findings: []
- reference: PMID:40265508
  title: Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.
  findings: []
- reference: PMID:32776570
  title: 'Cognitive-behavioral therapy for avoidant/restrictive food intake disorder: Feasibility, acceptability, and proof-of-concept for children and adolescents.'
  findings: []
- reference: PMID:34423319
  title: Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
  findings: []
- reference: PMID:41803077
  title: An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
  title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
  title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
  findings: []
- reference: url:https://clinicaltrials.gov/api/v2/studies/NCT06110806
  title: https://clinicaltrials.gov/api/v2/studies/NCT06110806
  findings: []
- reference: clinicaltrials:NCT02963220
  title: 'Cognitive-Behavioral Therapy for Avoidant/Restrictive Eating Disorder: A Treatment Development and Pilot Study'
  findings: []
- reference: clinicaltrials:NCT03778216
  title: Treating Avoidant/Restrictive Food Intake Disorder (ARFID) Using Family-Based Treatment
  findings: []
- reference: clinicaltrials:NCT05954728
  title: Cognitive and Neural Mechanisms of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder
  findings: []
- reference: clinicaltrials:NCT06110806
  title: Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
  title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
  findings: []
- reference: PMID:41284261
  title: Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
  findings: []
- reference: PMID:34177659
  title: Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
  findings: []
- reference: clinicaltrials:NCT06420232
  title: Protocol for Using a Weighted Blanket to Treat Anxiety Related to Trying New Foods in the Pediatric Population
  findings: []
- reference: PMID:35674869
  title: The Neurology and Psychopathology of Pica.
  findings: []
clinical_trials:
- name: NCT04450771
  description: Completed randomized comparison of family-based treatment and psychoeducational motivational therapy in underweight children with ARFID. Published results favor FBT-ARFID for weight gain, with no overall between-group difference in ARFID symptom improvement.
  phase: NOT_APPLICABLE
  status: COMPLETED
  evidence:
  - reference: PMID:42019720
    reference_title: 'Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'CLINICAL TRIAL REGISTRATION INFORMATION: Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. https://clinicaltrials.gov/study/NCT04450771.'
    explanation: Links the completed registered trial to its 2026 outcome publication.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: completed, actual enrollment 98, ages 6-12, behavioral intervention with phase not applicable. The publication reports end-of-treatment outcomes; it does not establish long-term durability.'
- name: NCT02963220
  description: Completed single-group CBT-AR pilot with separate youth and adult outcome publications. The uncontrolled design evaluates feasibility and preliminary change; it does not establish comparative efficacy.
  phase: NOT_APPLICABLE
  status: COMPLETED
  evidence:
  - reference: clinicaltrials:NCT02963220
    reference_title: 'Cognitive-Behavioral Therapy for Avoidant/Restrictive Eating Disorder: A Treatment Development and Pilot Study'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The primary aim of this study is to pilot cognitive behavioral therapy (CBT-AR)for avoidant/restrictive food intake disorder (ARFID) in one study for children and adolescents (ages 10-17 years) and one study for adults (ages 18-65 years).
    explanation: Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: completed, actual enrollment 35. Clinical outcomes are reported in PMID:32776570 and PMID:34423319; the imaging subset is reported in PMID:41803077.'
- name: NCT03778216
  description: Completed feasibility study of family-based treatment compared with usual care using a randomized crossover design.
  phase: NOT_APPLICABLE
  status: COMPLETED
  evidence:
  - reference: clinicaltrials:NCT03778216
    reference_title: Treating Avoidant/Restrictive Food Intake Disorder (ARFID) Using Family-Based Treatment
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This randomized controlled crossover trial (RCCT) will test the feasibility and acceptability of a novel intervention, Family-Based Treatment of Avoidant/Restrictive Food Intake Disorder (FBT-ARFID) for patients ages 5-12 years old.
    explanation: Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: completed, actual enrollment 28. The cached summary describes planned aims, not proof of benefit.'
- name: NCT05954728
  description: Randomized comparison of CBT-AR with nutrition counseling, studying cognitive and neural mechanisms in youth.
  phase: NOT_APPLICABLE
  status: COMPLETED
  evidence:
  - reference: clinicaltrials:NCT05954728
    reference_title: Cognitive and Neural Mechanisms of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study is a randomized controlledlinical trial, assessing the efficacy of cognitive- behavioral therapy (CBT-AR) and nutrition counseling for avoidant/restrictive food intake disorder (ARFID) for children and adolescents (ages 10-18 years).
    explanation: Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: completed, actual enrollment 53, completion March 2026. No results were posted in that registry record at the time of review; completion alone does not establish efficacy.'
- name: NCT06110806
  description: Single-group feasibility study of family-based mindfulness and interoceptive exposure. The registry records early termination; the planned primary acceptability outcome was not collected.
  phase: NOT_APPLICABLE
  status: TERMINATED
  evidence:
  - reference: clinicaltrials:NCT06110806
    reference_title: Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This project aims to establish the feasibility and acceptability of a comprehensive mind and body intervention; specifically a mindfulness-based interoceptive exposure (MBIE) for families of youth diagnosed with avoidant/restrictive food intake disorder (ARFID).
    explanation: Registry summary specifies the intervention and design; current status is from the live registry check described in notes.
  - reference: url:https://clinicaltrials.gov/api/v2/studies/NCT06110806
    reference_title: https://clinicaltrials.gov/api/v2/studies/NCT06110806
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Data not collected because 6 month visit not completed due to early termination of study.
    explanation: ClinicalTrials.gov NCT06110806, Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Posted primary-outcome record documents the missing six-month assessment after early termination.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: terminated for lack of agreement on a risk-mitigation plan. Posted results describe early termination and absence of the primary six-month assessment. This is not evidence of an effective established treatment.'
- name: NCT06420232
  description: Related feeding-anxiety pilot of a weighted blanket before meals. Eligibility required feeding challenges and caregiver-reported food anxiety, not a confirmed ARFID diagnosis. The study was terminated and does not establish an ARFID treatment.
  phase: NOT_APPLICABLE
  status: TERMINATED
  evidence:
  - reference: clinicaltrials:NCT06420232
    reference_title: Protocol for Using a Weighted Blanket to Treat Anxiety Related to Trying New Foods in the Pediatric Population
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This small experimental pilot study addresses the knowledge gap related to the use of weighted blankets for children with anxiety related to food and eating.
    explanation: Registry summary identifies the broader feeding-anxiety population, rather than an ARFID-specific efficacy trial.
  notes: 'ClinicalTrials.gov API checked 2026-09-27: termination attributed to recruitment and attrition challenges and the investigator graduating. Posted results have very few completers and no randomized comparison; they do not justify treating weighted blankets as established therapy.'
diagnosis:
- name: Clinical diagnostic assessment
  description: 'Assess persistent restriction or avoidance with at least one significant consequence: weight loss or growth faltering, nutrient deficiency, reliance on supplements or enteral feeding, or marked psychosocial impairment. Assess food availability and cultural practices, weight/shape motivations, and medical or psychiatric explanations. A coexisting disorder does not preclude ARFID when the feeding disturbance exceeds what that condition usually explains and warrants additional attention.'
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Criterion B states that the eating disorder cannot be better explained by the unavailability of food or a culturally accepted practice.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Food access and cultural practice are diagnostic exclusions.'
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: When an eating disorder occurs in the context of another condition or disorder, its severity exceeds that usually associated with the condition or disorder and warrants additional clinical attention
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Clarifies diagnostic coexistence with medical and psychiatric conditions.'
  - reference: PMID:38718975
    reference_title: Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'avoidant/restrictive eating by volume/variety resulting in any of the following consequences: (a) weight loss/failure to gain weight; (b) nutritional deficiency; (c) supplemental feeding dependence; and (d) psychosocial impairment'
    explanation: Operational diagnostic assessment in a primary clinical study; impairment is not restricted to underweight.
- name: PARDI interview and dimensional screening
  description: The Pica, ARFID, and Rumination Disorder Interview assesses diagnosis, severity and all three overlapping presentations. NIAS and PARDI-AR-Q questionnaires can support screening and monitoring; screening alone does not establish that diagnostic exclusions are met.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: PARDI is a structured interview developed to assess the presence and severity of diagnoses for evaluation and treatment planning in clinical and research settings, specifically focusing on ARFID.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Supports the structured interview.'
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The NIAS addresses food restriction behaviors associated with the three eating patterns related to ARFID, namely appetite, fear, and sensory sensitivity.
    explanation: 'Full text of PMID:38849953 (Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.) retrieved through PMC/BioC. Supports dimensional screening rather than a stand-alone diagnostic biomarker.'
- name: Nutritional and medical evaluation
  description: Review growth trajectories, weight change, diet variety, vital signs and signs of nutrient deficiency. Laboratory evaluation is guided by dietary omissions, nutritional status and possible alternative diagnoses; brain imaging and appetite-hormone assays are research measures rather than established ARFID diagnostic tests.
  evidence:
  - reference: PMID:38753906
    reference_title: Avoidant Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnosis involves a comprehensive medical, nutritional, and psychological evaluation to assess the patient's physical health, eating behaviors, and mental well-being.
    explanation: Supports multidisciplinary assessment of the clinical syndrome.
progression:
- phase: Variable persistence and remission
  age_range: 9-23 years at baseline in the prospective cohort
  notes: In a prospective cohort of 100 participants with full or subthreshold ARFID, 44% retained their original diagnosis across both annual follow-ups. Outcome estimates depended on how subthreshold illness was classified. Follow-up combined structured interviews and chart review; the sample was predominantly White and was not a population prevalence sample. Three participants developed anorexia nervosa while retaining restrictive eating symptoms, emphasizing reassessment of weight/shape motivation over time.
  evidence:
  - reference: PMID:38718975
    reference_title: Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In the full sample (N = 100), 44% (n = 44) persisted in their original diagnosis across both follow-ups, while 12% (n = 12) achieved remission at Year 1 that was sustained through Year 2.
    explanation: Uses the full-text longitudinal trajectory counts rather than converting the abstract wording of roughly half into an exact universal prognosis.
  - reference: PMID:38718975
    reference_title: Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: three participants (3%) experienced diagnostic shift to another the restricting type of AN (ANr) at Year 1 and retained ANr at Year 2.
    explanation: Observed crossover in this cohort; not a lifetime risk estimate.
biochemical:
- name: Fasting plasma cholecystokinin
  notes: Research association, not a diagnostic test. A case-control study found higher fasting CCK in full/subthreshold ARFID after adjustment for age, sex and BMI percentile, but no within-ARFID association with subjective appetite or symptom severity. A later two-year observational study linked decreases in CCK to improvement in lack-of-interest severity, not overall ARFID severity. Higher CCK in the lack-of-interest group was significant at year 1 only, with no significant difference at baseline or year 2. Causality and the contribution of nutritional state remain unresolved.
  evidence:
  - reference: PMID:35830620
    reference_title: Elevated Fasting Satiety-Promoting Cholecystokinin (CCK) in Avoidant/Restrictive Food Intake Disorder Compared to Healthy Controls.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Fasting CCK was higher in those with full/subthreshold ARFID versus HCs with a large effect
    explanation: Case-control elevation after adjustment for age, sex and BMI percentile.
  - reference: PMID:35830620
    reference_title: Elevated Fasting Satiety-Promoting Cholecystokinin (CCK) in Avoidant/Restrictive Food Intake Disorder Compared to Healthy Controls.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Within the ARFID group, CCK was not significantly related to BMI percentile, subjective appetite ratings, or ARFID characteristic measures.
    explanation: The initial study did not establish that higher CCK tracked subjective appetite or clinical severity within ARFID.
  - reference: PMID:42159358
    reference_title: Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, there was no significant difference between the groups in fasting CCK at Baseline or Year 2.
    explanation: The lack-of-interest presentation contrast was significant at only one follow-up, not consistently across timepoints.
  - reference: PMID:42159358
    reference_title: Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: greater decreases in fasting CCK from Baseline to Years 1 and 2 were associated with greater decreases in lack of interest severity scores
    explanation: Longitudinal association in a cohort with substantial attrition and complete-case endocrine analyses; not experimental evidence that lowering CCK treats ARFID.
- name: Fasting plasma ghrelin
  notes: Research measure rather than an established diagnostic biomarker. In a two-year ARFID cohort, fasting ghrelin did not differ by lack-of-interest presentation. Increases in ghrelin were associated with lower overall ARFID severity at follow-up, while associations with lack-of-interest severity were not significant. These observational findings do not establish a generalized ghrelin deficiency or efficacy of ghrelin treatment.
  evidence:
  - reference: PMID:42159358
    reference_title: Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: there were no differences in fasting ghrelin between participants that met versus did not meet cut-off for ARFID-lack of interest across timepoints.
    explanation: Preserves the negative presentation-specific comparison.
  - reference: PMID:42159358
    reference_title: Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: greater increases in fasting ghrelin from Baseline to Years 1 and 2 were associated with greater decreases in ARFID severity scores at Years 1 (f2 = .15) and 2 (f2 = .23), respectively.
    explanation: The reported association held at both annual follow-ups, but causal direction and treatment relevance remain untested.
imaging_findings:
- name: Greater frontal cortical thickness in children with ARFID-like symptoms
  modality: MRI
  diagnostic: false
  located_in:
    preferred_term: frontal cortex
    term:
      id: UBERON:0001870
      label: frontal cortex
  description: Cross-sectional Generation R analysis found greater frontal and superior frontal cortical thickness in children with ARFID-like symptoms; the differences persisted after BMI adjustment. Classification used an index rather than a diagnostic interview. No significant regional volume or surface-area differences were found in the prespecified regions, and exploratory findings did not survive multiple-comparison correction.
  notes: Research association, not an individual diagnostic marker. The study does not establish impaired synaptic pruning or causal executive dysfunction. Full-text results and Table 1 report 121 children with symptoms and 1,856 without; the abstract has an inconsistent comparator count.
  evidence:
  - reference: PMID:39623765
    reference_title: 'Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neuroanatomical findings identified significantly greater frontal (p = .00743; d = 0.21) and superior frontal (p = 6.56E-04; d = 0.28) cortical thickness among children with ARFID symptoms.
    explanation: The abstract reports a cortical-thickness association, not evidence for a cellular lesion.
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No observable differences in the regional surface area or volume of hypothesised regions were identified.
    explanation: 'Full text of PMID:39623765 (Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.) retrieved through PMC/BioC. Preserves the negative anatomical outcomes.'
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As such, the work in this study is unable to provide conclusive information regarding neural correlates associated with a clinical ARFID diagnosis, meaning the full generalisability to youth formally diagnosed with ARFID is unknown.
    explanation: 'Full text of PMID:39623765 (Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.) retrieved through PMC/BioC. Index-defined symptom group in a population cohort; clinical diagnostic generalization remains unresolved.'
- name: Reduced food-cue anterior cingulate response following CBT-AR
  modality: FUNCTIONAL_MRI
  diagnostic: false
  located_in:
    preferred_term: anterior cingulate cortex
    term:
      id: UBERON:0009835
      label: anterior cingulate cortex
  description: An exploratory analysis of an uncontrolled CBT-AR pilot found reduced right anterior cingulate food-versus-object activation in participants with paired scans. Baseline activation did not significantly predict symptom change or remission; anterior insula and amygdala activation did not significantly change. The anterior cingulate change no longer reached conventional significance after exploratory adjustment for trait anxiety.
  notes: Research treatment correlate, not proof of a causal treatment mechanism or a treatment-selection biomarker. This is a subset of previously published CBT-AR and neurobiology participants, not an independent replication.
  evidence:
  - reference: PMID:41803077
    reference_title: An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: youth with ARFID viewed images of food and non-food in a fasted state at pre-treatment (N = 24) and a subset (N = 14) also completed post-treatment scans.
    explanation: Small paired-imaging subset of the open trial.
  - reference: PMID:41803077
    reference_title: An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Pre-treatment activation in response to food versus objects was not associated with changes in ARFID severity or remission post-treatment.
    explanation: The baseline measure did not significantly predict clinical response.
  - reference: PMID:41803077
    reference_title: An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There were no significant pre- to post-treatment changes in the aINS or the amygdala.
    explanation: Negative regional results prevent generalized salience-network normalization claims.
  - reference: PMID:41803077
    reference_title: An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: with lower activation in the neural response to food cues from pre- to post-treatment in the ACC, with a slight attenuation in the significance level p(FWE)=.082 (cluster level) and effect size (d=.66).  # codespell:ignore fwe
    explanation: The anxiety-adjusted exploratory result did not meet conventional statistical significance.
has_subtypes:
- name: Sensory-sensitivity presentation
  description: Avoidance based on sensory properties of food and rigid preferences. A clinical presentation that can overlap with the other dimensions, not a separate Mendelian disorder.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Sensory subtype was characterised by high probabilities of sensory sensitivity (0.83) and rigid eating behaviours (0.73)
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Empirically derived sensory class in secondary-care children and adolescents.'
- name: Lack-of-interest presentation
  description: Low appetite or interest in eating and difficulty consuming sufficient amounts; can coexist with sensory sensitivity or fear.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Lack of Interest subtype was characterised by high probabilities of lack of appetite (0.85) and lack of interest in eating or food (1.0)
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. The class distinguishes low appetite from other reasons for restriction.'
- name: Fear-of-aversive-consequences presentation
  description: Avoidance motivated by anticipated choking, vomiting, pain or other aversive effects; may have relatively acute onset in clinical cohorts.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Fear subtype was characterised by high probability of fear of aversive consequences of eating (0.97)
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. Empirical clinical grouping; not a separate diagnostic category or proof that every case follows a traumatic event.'
- name: Combined presentation
  description: Co-occurring dimensions are common. The largest class in a UK and Republic of Ireland secondary-care study combined sensory sensitivity and lack of interest. That study-specific class does not define a universal fourth biological subtype.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    reference_title: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the most prevalent class, comprising 38% of the sample, was the Combined Subtype characterised by a combination of Lack of Interest Subtype and Sensory Subtype.
    explanation: 'Full text of PMID:38333539 (Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.) retrieved through PMC/BioC. The class distribution depends on the study population and ascertainment.'
📚

References & Deep Research

References

33
PMID:38849953
Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment.
No top-level findings curated for this source.
PMID:36723946
Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years.
No top-level findings curated for this source.
PMID:39964683
Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder.
No top-level findings curated for this source.
PMID:38718975
Prospective 2-Year Course and Predictors of Outcome in Avoidant/Restrictive Food Intake Disorder.
No top-level findings curated for this source.
PMID:39623765
Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis of a paediatric population.
No top-level findings curated for this source.
PMID:36527163
What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature.
No top-level findings curated for this source.
PMID:37990202
ARFID Genes and Environment (ARFID-GEN): study protocol.
No top-level findings curated for this source.
PMID:38333539
Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis.
No top-level findings curated for this source.
PMID:37950288
Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder.
No top-level findings curated for this source.
PMID:40568462
Avoidant/Restrictive Food Intake Disorder in Adult Patients with Gastrointestinal Diseases: A Concept Analysis Using Evolutionary Approach.
No top-level findings curated for this source.
PMID:39275348
Development and Management of Avoidant/Restrictive Food Intake Disorder and Food Neophobia in Pediatric Patients with Food Allergy: A Comprehensive Review.
No top-level findings curated for this source.
PMID:42019720
Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial.
No top-level findings curated for this source.
PMID:38753906
Avoidant Restrictive Food Intake Disorder.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11157884/unicode
No top-level findings curated for this source.
url:https://pmc.ncbi.nlm.nih.gov/articles/PMC10108140/
What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review of the literature - PMC
No top-level findings curated for this source.
PMID:35830620
Elevated Fasting Satiety-Promoting Cholecystokinin (CCK) in Avoidant/Restrictive Food Intake Disorder Compared to Healthy Controls.
No top-level findings curated for this source.
PMID:42159358
Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms.
No top-level findings curated for this source.
PMID:40265508
Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.
No top-level findings curated for this source.
PMID:32776570
Cognitive-behavioral therapy for avoidant/restrictive food intake disorder: Feasibility, acceptability, and proof-of-concept for children and adolescents.
No top-level findings curated for this source.
PMID:34423319
Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder.
No top-level findings curated for this source.
PMID:41803077
An Exploratory Study of Neural Response to Food Cues Following Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC12062856/unicode
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC10850399/unicode
No top-level findings curated for this source.
url:https://clinicaltrials.gov/api/v2/studies/NCT06110806
https://clinicaltrials.gov/api/v2/studies/NCT06110806
No top-level findings curated for this source.
clinicaltrials:NCT02963220
Cognitive-Behavioral Therapy for Avoidant/Restrictive Eating Disorder: A Treatment Development and Pilot Study
No top-level findings curated for this source.
clinicaltrials:NCT03778216
Treating Avoidant/Restrictive Food Intake Disorder (ARFID) Using Family-Based Treatment
No top-level findings curated for this source.
clinicaltrials:NCT05954728
Cognitive and Neural Mechanisms of Cognitive-behavioral Therapy for Avoidant/Restrictive Food Intake Disorder
No top-level findings curated for this source.
clinicaltrials:NCT06110806
Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC11397472/unicode
No top-level findings curated for this source.
PMID:41284261
Prevalence, Characteristics, and Genetic Architecture of Avoidant/Restrictive Food Intake Phenotypes.
No top-level findings curated for this source.
PMID:34177659
Estimating the Prevalence and Genetic Risk Mechanisms of ARFID in a Large Autism Cohort.
No top-level findings curated for this source.
clinicaltrials:NCT06420232
Protocol for Using a Weighted Blanket to Treat Anxiety Related to Trying New Foods in the Pediatric Population
No top-level findings curated for this source.
PMID:35674869
The Neurology and Psychopathology of Pica.
No top-level findings curated for this source.

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Review ARFID mechanisms, clinical findings, genetics and treatment evidence against cached full texts · 2026-09-27T12:11:43Z · View source

Reviewed the full disorder entry, both validated deep-research reports and their citation lists, and cached primary/review evidence. Disease identity is MONDO:7770002; this is an eligible psychiatric disorder, not an infectious or environmental disease. No prior REVIEW event was present. The branch was created from current main and its base was rechecked before this review. Full-text audit: consumed scientific text, methods, results, tables and figure legends for the Swedish twin study (36723946), food-cue fMRI (39964683), pleasure study (37950288), prospective course (38718975), neurobiology/treatment review (38849953), pediatric epidemiology review (36527163), latent-class study (38333539), Generation R MRI study (39623765), food-allergy review (39275348), adult GI concept analysis (40568462), and ARFID-GEN protocol (37990202). Recovered readable full texts through generated PMC/BioC or NCBI Bookshelf cache entries when the original PMID held an abstract or PDF extraction artifacts. StatPearls was tagged and its clinical evaluation, complications and management sections checked alongside primary clinical evidence. Added and read primary full texts: child and adult CBT-AR pilots (32776570, 34423319), 2026 FBT randomized trial (42019720), CCK case-control study (35830620), longitudinal CCK/ghrelin study (42159358), retrospective mirtazapine study (40265508), CBT-AR imaging follow-up (41803077), MoBa ARFI genetics (41284261), and SPARK ARFID-risk genetics (34177659; also read its generated DOI PDF). Several imaging, endocrine, pleasure and treatment reports use overlapping NIMH participants, so they are not counted as independent replications. Main corrections: removed unsupported taste-receptor, enteroendocrine-cell and specific neuronal annotations. Kept imaging/endocrine associations distinct from initiating causes. Preserved null hypothalamus group contrast, null fear-severity correlation, negative insula findings, depression-related attenuation of pleasure differences, and anxiety-adjusted attenuation of the CBT imaging result. The longitudinal CCK group difference occurred only at year 1. The source misspelling of amygdala is retained only inside an exact quotation. The MRI abstract's comparator-count inconsistency is resolved using full-text results and Table 1. Treatment evidence now distinguishes the 98-child FBT trial's weight benefit from its lack of overall symptom superiority, uncontrolled CBT feasibility findings, and nonrandomized inpatient mirtazapine associations. Removed the incorrectly attributed tube-weaning result from nutrition-only treatment. ClinicalTrials.gov records checked 2026-09-27: NCT04450771, NCT02963220, NCT03778216 and NCT05954728 completed; NCT06110806 terminated with the primary six-month assessment uncollected. NCT06420232 was also terminated; its eligibility was feeding anxiety rather than confirmed ARFID, so it is explicitly a related pilot. Its tiny results do not establish therapy efficacy. Genetics: preserved the broad childhood ascertainment and sibling-contrast limitations of the twin estimate. MoBa ADCY3 association concerns ARFI traits, not confirmed ARFID; SPARK rs13177031 is a risk-score association near ZSWIM6 without demonstrated variant-to-gene regulation. Both gene relationships remain UNKNOWN, with no invented Mendelian inheritance, penetrance or functional consequence. The 2025 ARFID-GEN conference abstract (10.1016/j.euroneuro.2025.08.308) still describes future GWAS results; it is not evidence for a discovered locus. TAS2R claims in the reports concern generic taste biology, not verified ARFID causation, and were not imported. Content-completeness assessment: 1. Phenotypes: adequate. Thirteen findings cover restriction, appetite, feeding, weight/growth and major malnutrition complications; anxiety/autistic behavior are labeled comorbid context. No unsupported universal frequencies. Eleven of thirteen have causal inlinks; comorbid anxiety/autistic behavior intentionally have no ARFID-causes-comorbidity edge. 2. Presentations: adequate. Sensory, low-interest, fear and study-derived combined presentations are explicit, with overlap and ascertainment limitations; they are not presented as separate Mendelian entities. 3. Mechanisms: adequate. Behavioral drivers, shared liability, restrictive intake, nutritional consequences and direct psychosocial impairment are distinguished. Cellular circuit claims are not inferred from region-level imaging. Conditioned taste aversion from the reports is a limited conceptual analogue, not a validated whole-disorder animal model. 4. Treatments/trials: adequate. CBT-AR, FBT, nutritional rehabilitation/refeeding monitoring and adjunctive off-label medications are covered; all verified report trial leads are accounted for. No trial registration is treated as proof of benefit. 5. Genetics: adequate. Twin estimates and common-variant findings include study-specific phenotyping and uncertainty. No monogenic causal gene or penetrance estimate was established. 6. Diagnostics/biomarkers: adequate. Diagnostic exclusions/coexistence, PARDI/NIAS screening, individualized medical evaluation, research hormones and imaging are separated. Necessary allergen avoidance is not equated with ARFID. 7. References: adequate. High-value primary studies replace protocol, introductory or review-only support where available. Full-text caveats and negative findings changed the curation materially. Supplement-only analyses not retrieved were not used as primary quantitative evidence. Failed/recaptcha cache artifacts are excluded from the PR. 8. Overall consumption: adequate. Broad clinical, mechanistic and treatment themes were used, with explicit limits on causal, diagnostic and cross-population extrapolation. No blocking omission identified. Validation: authoritative batched schema, term and reference validation passed: 97 snippets, 129 titles, zero skipped/unavailable, zero issues. Entity/causal targets, coarse phenotype bindings, source-defect claims and snippet boundaries passed. The prose-figure audit's lone flag is a parsing artifact within the valid conversion of 0.3%-15.5% to 300-15,500 per 100,000; the text identifies heterogeneous screening studies rather than a pooled diagnostic prevalence. Both scoped data tests passed. Repository ratchets for snippet length, title quotations, snippet grading and reference titles passed without new violations; node-class examples also passed.

Enrich ARFID from Falcon deep research (appetitive neurobiology, GI/allergy precipitants, LCA subtypes) · 2026-07-29T23:34:41Z · View source

Falcon (Edison) deep-research pass. Added four abstract-verified citations across existing nodes: reduced anticipatory food reward specific to the lack-of-interest profile (Dolan 2023, PMID:37950288, SUPPORT + PARTIAL after depression adjustment) on the Low Appetite node; GI-disease and food-allergy fear precipitants (Che 2025, PMID:40568462; Nocerino 2024, PMID:39275348) on the Fear of Aversive Consequences node; and empirical latent-class subtype structure - Fear/Lack-of-Interest/Sensory/Combined, Combined most common (Sanchez-Cerezo 2024, PMID:38333539) on the convergent Restriction node. Full-text-only medical-complication and PARDI-psychometric numbers and the unvalidated ZSWIM6 locus were rejected. just validate passes.

Create: Avoidant Restrictive Food Intake Disorder · 2026-07-29T22:49:03Z · View source

Created the ARFID MONDO:7770002 entry. Deep research via claude_code provider; all PMIDs fetched and snippets verified as exact abstract substrings; ontology terms OAK-verified. Models the three DSM-5 driver presentations - sensory sensitivity, low appetite/interest, and fear of aversive consequences - converging on food restriction, with the absence of body-image disturbance and drive for thinness made central as the contrast with anorexia nervosa; plus nutritional/energy failure and neurodevelopmental-anxiety comorbidity. Includes phenotypes, structured prevalence, treatments CBT-AR / FBT-ARFID / nutritional rehabilitation / off-label pharmacotherapy, and AN and Pica differentials. just validate passes.

Claude Code ▸
Avoidant/Restrictive Food Intake Disorder (ARFID): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 11 citations 2026-07-29T22:18:01.256319

Avoidant/Restrictive Food Intake Disorder (ARFID): Comprehensive Research Report

1. Disease Information

Overview: Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding and eating disorder characterized by persistent failure to meet nutritional and/or energy needs through avoidant or restrictive food intake, without the body image disturbance, fear of weight gain, or drive for thinness that defines anorexia nervosa (AN) or bulimia nervosa (BN). It was introduced as a new diagnostic category in DSM-5 (2013), replacing and substantially expanding the DSM-IV-TR diagnosis "Feeding Disorder of Infancy or Early Childhood" (previously restricted to onset before age 6) (PMID: 38849953; NBK603710).

Key identifiers: - ICD-11: 6B83 Avoidant-restrictive food intake disorder, under "Feeding or Eating Disorders" (findacode.com/ICD-11 MMS; mrcpsych.uk) - DSM-5 code: 307.59 - MONDO: A specific MONDO CURIE could not be independently confirmed via web search in this session — dismech curation should verify directly via uv run runoak -i sqlite:obo:mondo search "avoidant restrictive food intake disorder" per project convention rather than relying on this report. - OMIM: Not applicable — ARFID is not modeled in OMIM as a monogenic/Mendelian disorder; it is a polygenic, multifactorial psychiatric/behavioral condition. - Orphanet: Not listed as a rare disease entity (ARFID is a common psychiatric condition, not orphan-classified). - MeSH: Falls under "Feeding and Eating Disorders" (MeSH D000066942 Avoidant Restrictive Food Intake Disorder was added as an indexed term after 2013 introduction).

Synonyms/alternative names: Selective eating disorder (older/lay term); "picky eating disorder" (lay term, imprecise); food avoidance emotional disorder (an earlier, related but not identical construct); functional dysphagia (as a fear-driven ARFID presentation); food neophobia (a component construct, not synonymous); previously "feeding disorder of infancy or early childhood" (DSM-IV, now subsumed).

Evidence base characteristics: The literature is derived from a mix of sources — clinical cohort studies from specialized eating-disorder and feeding programs (aggregated disease-level clinical data), population-based birth-cohort and twin registries (e.g., the Swedish Child and Adolescent Twin Study, CATSS; the Dutch Generation R Study), self-report/parent-report screening instrument validation studies, and a small but growing number of neuroimaging and genetic (GWAS) studies. There is essentially no OMIM/ClinVar-style individual-variant clinical data, since ARFID is not caused by identified single-gene mutations.

2. Etiology

Disease Causal Factors

ARFID is multifactorial, arising from the interaction of genetic predisposition, neurobiological traits (sensory processing, appetite regulation, fear/threat circuitry), temperament, medical/gastrointestinal history, and environmental/psychosocial triggers (PMID: 38849953). There is no single necessary or sufficient cause; three overlapping symptom "drivers" recognized in DSM-5 map onto at least partially distinct etiological pathways: 1. Sensory sensitivity to taste/texture/smell/appearance of food 2. Apparent lack of interest in eating or food (low appetite/interoceptive drive) 3. Fear of aversive consequences of eating (choking, vomiting, allergic reaction, GI pain) — often following a precipitating traumatic eating event

Genetic Risk Factors

  • Heritability: The largest twin study to date (Dinkler et al., 2023, JAMA Psychiatry, PMID 36723946) analyzed 16,951 twin pairs (33,902 children, ages 6–12) from the Swedish CATSS registry; 682 children (2.0%) met a "broad ARFID phenotype." Heritability was estimated at 0.79 (95% CI, 0.70–0.85), with nonshared environmental factors contributing 0.21 (95% CI, 0.15–0.30), and shared environment contributing negligibly. This heritability estimate is comparable to or higher than other eating disorders and similar to neurodevelopmental disorders. Sensitivity analyses excluding children with autism (h² = 0.77) or medical conditions (h² = 0.79) gave similar estimates, indicating this is not solely an artifact of comorbid autism.
  • Candidate mechanism — taste receptor genetics: Polymorphisms in TAS2R bitter-taste receptor genes are associated with "supertaster" phenotypes (heightened sensitivity to 6-n-propylthiouracil/PROP bitterness), proposed as a heritable substrate for the sensory-sensitivity ARFID subtype (PMID: 38849953).
  • GWAS status: The ARFID-GEN study (ARFID Genes and Environment; PMID 37990202, BMC Psychiatry 2023) is the first dedicated genome-wide association study, collecting phenotypic questionnaires and saliva DNA from a cohort spanning ages 7–88 (target N=3,190+). Rationale: "High twin-based heritability recently reported for ARFID... motivated the undertaking of this genome-wide association study" — SNP-based heritability, GWAS, genetic correlations with other psychiatric/anthropometric traits, polygenic risk scores, and rare copy-number variant (CNV) analysis are planned. As of mid-2025 conference abstracts (T25, European Neuropsychopharmacology), preliminary meta-analyses had not yet reached genome-wide significance for individual loci, attributed to modest sample size at that stage; full ARFID-GEN results are pending.
  • Neurodevelopmental genetic overlap: Strong genetic/phenotypic correlation with autism spectrum disorder (ASD) and ADHD — children with ARFID are ~14x more likely to have a co-occurring ASD diagnosis and ~9x more likely to have ADHD than children without ARFID.

Environmental Risk Factors

  • Early neurodevelopmental problems (NDPs): A Japanese birth-cohort study found children in the highest-risk NDP percentile had roughly 3x higher odds of suspected ARFID; NDPs predictive of later ARFID included problems with general development, communication/language, attention/concentration, social interaction, and sleep (PMC10242837).
  • Precipitating/traumatic triggers: In one cohort, 71.4% of ARFID patients reported an identifiable triggering event — choking, vomiting (self or witnessed), abdominal pain, bullying, bereavement, medication initiation, or a food-allergy scare (PMID: 38849953).
  • Perpetuating factors: Parental accommodation of restricted "safe foods," parental anxiety/frustration at mealtimes, and negative reinforcement of avoidance behavior sustain the disorder once established.
  • Medical/GI comorbidity as a risk pathway: Gastroesophageal reflux disease (GERD), eosinophilic esophagitis, inflammatory bowel disease, food allergies, and structural oropharyngeal abnormalities are recognized antecedent/contributing conditions, particularly for the fear-of-aversive-consequences subtype.
  • Sex: Unlike AN/BN, ARFID shows a more even or even male-skewed sex ratio in pediatric clinical samples (21–50% male, vs. the strong female predominance in AN/BN).

Protective Factors

No genetic protective variants have been reported. Environmentally, early, low-pressure, repeated exposure to food variety in infancy/toddlerhood and responsive (non-coercive) feeding practices are associated with lower risk of persistent selective eating, though formal protective-factor data (as distinct from treatment response) remain limited.

Gene-Environment Interactions

The prevailing model is a diathesis-stress framework: an inherited predisposition (heightened sensory reactivity, anxious temperament, or blunted appetite drive) is unmasked or amplified by an environmental trigger (an aversive eating event, GI illness, or high-NDP-risk developmental trajectory), which is then perpetuated by feeding-environment reinforcement patterns (PMID: 38849953; PMC13050801, "Risk factors for avoidant/restrictive food intake disorder in children: A systematic review," 2026).

3. Phenotypes

ARFID phenotypes are typically organized under DSM-5's three symptom drivers, each with a partially distinct clinical/demographic profile.

A. Sensory Sensitivity / Selective Eating

  • Type: Behavioral/sensory-processing phenotype
  • Onset: Often earliest, from infancy or toddlerhood
  • Characteristics: Refusal based on texture, temperature, color, smell, or presentation of food; narrow accepted-food repertoire; frequently seen with concurrent ASD (13–50% comorbidity, PMID 38849953)
  • Frequency/demographics: More common in boys (51.2% vs. 31.5% in girls, P=0.007) and in younger children (66.7% at ages 5–9 vs. 22.2% at ages 15–18)
  • Suggested HP terms: HP:0011968 Feeding difficulties; HP:0000745 Irritability (secondary); consider HP:0032443 Restrictive eating behavior or generic HP:0011968/HP:0410030-class feeding-behavior terms — HPO does not yet carry an ARFID-specific granular term; curators should verify current HPO subtree under "Feeding difficulties" (HP:0011968) for the closest fit.

B. Apparent Lack of Interest in Eating / Low Appetite ("Inappetence")

  • Type: Behavioral/physiological (appetite regulation) phenotype
  • Onset: Often present from infancy
  • Characteristics: Low interest in food, easy distractibility during meals, forgetting to eat, rapid satiety
  • Neuroendocrine correlates: Higher fasting ghrelin, elevated postprandial peptide YY (PYY), elevated fasting cholecystokinin (CCK) versus healthy controls (PMID 38849953, citing Murray et al. 2022 and Becker et al. 2021) — though patterns differ from anorexia nervosa (see Mechanism section)
  • Suggested HP terms: HP:0004396 Decreased body weight, HP:0001508 Failure to thrive, HP:0011968 Feeding difficulties

C. Fear of Aversive Consequences

  • Type: Anxiety-driven behavioral phenotype
  • Onset: Often later (school-age/adolescence), typically post-traumatic-event
  • Characteristics: Fear of choking, vomiting, allergic reaction, or GI pain; avoidance of specific food textures/consistencies (often solids); overlaps with specific phobia and emetophobia
  • Frequency: Associated with the highest anxiety-trait correlations among the three profiles
  • Suggested HP terms: HP:0000739 Anxiety, HP:0002024 Vomiting-related avoidance (via association), consider functional dysphagia-related terms

Secondary/Systemic Phenotypes (from chronic malnutrition — see Sections 6–7)

  • Growth failure / short stature: HP:0001508 Failure to thrive; HP:0004322 Short stature
  • Amenorrhea (primary/secondary): HP:0000786 Secondary amenorrhea
  • Anemia: HP:0001903
  • Bradycardia: HP:0001662
  • Osteopenia/reduced bone mineral density: HP:0000939 Osteopenia
  • Delayed puberty: HP:0000823

Quality of Life Impact

Psychosocial impairment is a core diagnostic criterion (not merely a consequence): impaired ability to eat with others, social isolation at school, family mealtime conflict, and — in fear-driven presentations — significant distress/avoidance of eating-related social situations. Illness duration before diagnosis is notably long (12–33 months vs. 8–23 months for other eating disorders), prolonging cumulative QoL burden (PMID 38849953).

Symptom Progression

Course is more often chronic and stable than episodic; a prospective 2-year outcome study found nearly half of individuals continued to meet full ARFID criteria at follow-up, with only a minority achieving full remission (PMID 38718975). Persistence at 1 year was associated with greater sensory-sensitivity and lack-of-interest severity; remission at 2 years was associated with the fear-of-aversive-consequences profile.

4. Genetic/Molecular Information

  • Causal genes: None established — ARFID is not attributable to a single gene or chromosomal abnormality. It is modeled as a complex/polygenic behavioral-psychiatric trait, analogous in genetic architecture (per twin data) to neurodevelopmental disorders rather than to a monogenic syndrome.
  • Pathogenic variants: Not applicable in the Mendelian sense. No ClinVar/ACMG pathogenic-variant classifications exist for ARFID as a primary diagnosis.
  • Candidate/associated genes: TAS2R bitter-taste receptor family polymorphisms (sensory-subtype candidate, not yet GWAS-confirmed for ARFID specifically) (PMID 38849953).
  • GWAS status: ARFID-GEN (PMID 37990202) is the first ARFID-dedicated GWAS; SNP-heritability, polygenic risk score, and genetic-correlation analyses (versus AN, ASD, ADHD, anxiety, BMI) are underway/pending as of this writing (2026); a preceding preliminary GWAS of "childhood fussy eating and ARFID" (ScienceDirect abstract, 2023) had not reached genome-wide significance in early analyses.
  • Modifier genes: None specifically established; comorbid ASD/ADHD genetic liability likely acts as a shared/overlapping risk architecture rather than a discrete "modifier."
  • Epigenetics: No dedicated ARFID methylation/epigenomic studies were identified in this search; this remains an open gap.
  • Chromosomal abnormalities: None specifically implicated in idiopathic ARFID (distinguish from feeding difficulties secondary to known syndromic conditions, which are typically coded as symptoms of the underlying syndrome rather than as ARFID per se).

5. Environmental Information

  • Non-toxin environmental factors: No specific toxin, radiation, or occupational exposure is implicated (this is not an exposure-driven disease in the toxicological sense).
  • Lifestyle/behavioral factors: Feeding practices (parental pressure vs. accommodation), family mealtime structure, and repeated food exposure patterns strongly modulate course, though they are better characterized as perpetuating/ameliorating factors than primary causal exposures.
  • Infectious agents: Not directly causal, though acute GI infections/illness episodes are a recognized category of precipitating traumatic eating events (e.g., vomiting illness triggering food-specific fear).
  • Medical antecedents functioning as environmental risk: GERD, eosinophilic esophagitis, IBD, food allergy, and oropharyngeal/structural abnormalities are established antecedent medical conditions that can precipitate or maintain avoidant eating, especially in the fear-driven subtype (NBK603710).

6. Mechanism / Pathophysiology

The most current synthesis (Fonseca et al. 2024, Journal of Eating Disorders, PMID 38849953) proposes a three-dimensional neurobiological model mapping onto the three DSM-5 symptom drivers.

Domain 1 — Sensory Perception Alterations

  • Cellular/molecular basis: Heightened taste receptor sensitivity (TAS2R bitter-taste polymorphisms; "supertaster" phenotype linked to PROP bitterness sensitivity) produces intensified, aversive taste/texture experiences.
  • Processing mechanism: Individuals show sensory hyperresponsiveness — "faster, more intense, and longer-lasting responses to sensory stimuli," attributed to impaired regulation/organization of sensory-input intensity (PMID 38849953).
  • Neural substrate: Anterior insula implicated as the interoceptive/gustatory integration hub, though a food-cue fMRI study did not find greater insula activation in the ARFID-sensory-sensitivity subgroup versus controls (PMID 39964683), suggesting the insula's role may be more complex than a simple hyperactivation model.
  • Suggested GO terms: GO:0050909 sensory perception of taste; GO:0007605 sensory perception of sound (n/a); more specifically GO:0050916 sensory perception of sweet taste / GO:0001580 detection of chemical stimulus involved in sensory perception of bitter taste.
  • Suggested CL terms: CL:0000209 taste receptor cell.

Domain 2 — Appetite Homeostasis Dysregulation ("Inappetence")

  • Causal chain: Altered hypothalamic-insular signaling → blunted hunger/interoceptive drive → chronic low intake → malnutrition.
  • Central structures: Lateral hypothalamus (LH, feeding termination) and paraventricular nucleus (PVN, feeding initiation) integrate hunger/satiety; hunger increases, satiety inhibits hypothalamic activity in typical physiology, and this integration appears disrupted in the inappetence ARFID subtype.
  • Neuroimaging: Kerem et al. (cited in PMID 38849953) found hyperactivation of orbitofrontal cortex and anterior insula (food-anticipation/reward regions) in fasted ARFID patients with overweight/obesity versus normal-weight ARFID — an unexpected reward-circuit finding requiring replication.
  • Neuroendocrine profile (distinguishing ARFID from AN): Higher fasting ghrelin, elevated postprandial PYY, elevated fasting CCK, higher GLP-1; but low-weight ARFID shows lower total ghrelin around meals than AN and does not show AN's sustained post-meal PYY elevation (Becker et al. 2021, cited in PMID 38849953) — indicating a biologically distinct appetite-dysregulation signature from AN's fear/restraint-driven physiology. Aulinas et al. (2020) also found ARFID has fewer missed menses, higher total T3, and lower T4:T3 ratio versus AN.
  • Suggested GO terms: GO:0007631 feeding behavior; GO:0032099 negative regulation of appetite; GO:0032100 positive regulation of appetite.

Domain 3 — Negative Valence System Hyperactivation (Fear of Aversive Consequences)

  • Causal chain: Traumatic eating event (choking/vomiting/pain) → amygdala-dependent fear conditioning → hyperactivation of fear/threat circuitry → persistent conditioned avoidance of food/textures resembling the trigger.
  • Neural substrates: Amygdala (fear processing/learning; lateral amygdala integrates multimodal sensory input for conditioned/unconditioned stimulus association), medial prefrontal cortex (fear regulation), anterior cingulate cortex (emotional processing), hippocampus (contextual memory).
  • fMRI evidence: Youth with ARFID-fear subtype showed significantly greater amygdala activation versus healthy controls (mean difference 0.49, 95% CI 0.16–0.82, P=0.04) in response to aversive food-fear images; broader activation increases were also seen in anterior cingulate cortex, sensory association cortex, and supplementary motor cortex across ARFID groups generally (PMID 39964683).
  • Disgust as mediator: An exploratory study of 1,644 adults found that disgust fully mediated the association between anxiety and ARFID symptoms, implicating disgust-processing circuitry (insula, again) as a convergence point between the fear and sensory domains (PMID 38849953).
  • Suggested GO terms: GO:0007613 memory (fear-related); GO:0001662 behavioral fear response.

Structural Neuroimaging

The first structural MRI study of ARFID (Sader et al. 2025, J Child Psychol Psychiatry, PMID 39623765), using 1,977 10-year-olds from the population-based Dutch Generation R cohort, found children with ARFID-like symptoms had greater mean cortical thickness in bilateral superior frontal and frontal cortices compared to those without symptoms — the first evidence of a distinct structural neuroanatomical correlate, independent of the functional (fMRI) findings above.

Gut-Brain Axis

An emerging conceptual model (PMC11629072, "A Role for the Microbiota-Gut-Brain Axis in ARFID") proposes that the restricted diet characteristic of ARFID reduces gut microbial diversity, which may in turn affect homeostatic signaling, food reward, interoception, sensory sensitivity, and mood via microbial effects on inflammation, cortisol, and neurotransmitters (dopamine, serotonin) — potentially creating a self-reinforcing cycle in which dietary restriction itself worsens the neurobiological substrate maintaining the restriction.

Cellular/Tissue-Level Consequences of Chronic Malnutrition

Chronic undernutrition produces secondary tissue-level pathophysiology paralleling that of anorexia nervosa: reduced cardiac mass, bone-marrow suppression (anemia/leukopenia/thrombocytopenia), reduced bone mineral density (osteoblast/osteoclast imbalance from hypogonadotropic hypogonadism), and hepatic dysfunction from starvation-associated fatty infiltration.

Immune System Involvement

No primary autoimmune or immunodeficiency mechanism is implicated; the gut-brain-axis model above proposes a secondary, diet-driven inflammatory/immune modulation (via altered microbiota) rather than immune dysfunction as an initiating cause.

Molecular Profiling

No transcriptomic, proteomic, metabolomic, or single-cell datasets specific to ARFID were identified in this search — this is a significant data gap relative to the neuroimaging and genetic literature, consistent with ARFID being a recently defined (2013) diagnostic entity.

7. Anatomical Structures Affected

Organ/System Level

  • Primary system: Central nervous system (hypothalamus, amygdala, insula, prefrontal/cingulate cortex) — the behavioral/regulatory locus of disease.
  • Secondary/complication-driven systems (from chronic malnutrition, per NBK603710):
  • Cardiovascular: bradycardia, hypotension, arrhythmia, reduced cardiac mass, mitral valve prolapse, pericardial effusion, cardiomyopathy
  • Gastrointestinal: constipation, gastroparesis, GERD, dysphagia, functional dyspepsia
  • Endocrine/reproductive: hypothalamic amenorrhea, thyroid dysfunction, delayed puberty, osteopenia/osteoporosis
  • Renal: electrolyte imbalance, acute kidney injury (in severe refeeding contexts)
  • Hematologic: anemia, leukopenia, thrombocytopenia
  • Musculoskeletal: growth retardation, decreased muscle mass, rickets (severe pediatric cases)
  • Dermatologic: dry skin, hair loss (secondary to nutrient deficiency)

Suggested UBERON terms: UBERON:0000955 brain; UBERON:0001876 amygdala; UBERON:0002018 insular cortex; UBERON:0001870 frontal cortex; UBERON:0002037 cerebellum (n/a, not specifically implicated); UBERON:0000948 heart; UBERON:0001007 digestive system; UBERON:0002370 thymus (n/a).

Tissue/Cell Level

  • Neurons: amygdalar and hypothalamic neuronal populations implicated in fear-conditioning and appetite circuits (CL:0000540 neuron).
  • Taste receptor cells: CL:0000209 taste receptor cell — sensory-subtype substrate.
  • Enteroendocrine cells: ghrelin-, PYY-, and CCK-secreting gut enteroendocrine cells (CL:0000164 enteroendocrine cell) — implicated in the distinct appetite-hormone profile.

Subcellular Level

No specific subcellular/organellar pathology (e.g., mitochondrial, ER stress) has been described; this is a circuit-level, not organelle-level, disorder.

Localization

Bilateral/symmetric neuroanatomical findings reported to date (bilateral superior frontal cortical thickening; bilateral amygdala activation) — no lateralization pattern established.

8. Temporal Development

  • Age of onset: Frequently begins in infancy or early childhood, especially the "lack of interest" and "sensory sensitivity" subtypes, which are often present from the earliest feeding period; the "fear of aversive consequences" subtype more often emerges later (school-age/adolescence) following a discrete traumatic eating event. Mean age at clinical presentation across studies: 11.1–14.6 years (versus 14–16.7 years for anorexia nervosa) (PMID 38849953).
  • Onset pattern: Can be insidious (sensory/inappetence subtypes, present from infancy) or acute/precipitated (fear subtype, tied to a specific traumatic event).
  • Progression: Predominantly a chronic, stable course rather than episodic. A prospective 2-year study (PMID 38718975) found that ~half of participants persisted with full ARFID criteria at follow-up, and only 3% shifted diagnostically to anorexia nervosa. Illness duration prior to diagnosis (12–33 months) exceeds that typically seen in AN/BN (8–23 months), suggesting either slower recognition or genuinely more indolent onset.
  • Remission patterns: A minority of cases show spontaneous or treatment-associated remission; persistence is the modal outcome without intervention. Predictors differ by symptom driver: sensory-sensitivity and lack-of-interest severity predict 1-year persistence; fear-of-aversive-consequences severity predicts 2-year remission.
  • Critical periods: Early childhood (before age 6–7) is a key differentiation window, since normative "picky eating" is common under age 6 and typically resolves spontaneously — persistence beyond this window, combined with functional/nutritional impairment, is a key marker distinguishing ARFID from developmentally normal food selectivity (PMC12736178).
  • Course into adulthood: ARFID is increasingly recognized to persist into or first present in adulthood; adult clinical cohorts show slower treatment progress and less favorable weight-restoration trajectories than adults with anorexia nervosa, though overall treatment completion and improvement rates are reported as good (PMC10807227).

9. Inheritance and Population

Epidemiology

  • Community/general population prevalence: 0.3–15.5% (wide range reflecting instrument and population heterogeneity); general child-population estimates cluster around 0.35–3.2%; a large Dutch population cohort (Generation R, n=2,862) found 6.4% met ARFID-symptom criteria; adult general-population estimates 0.3–3.1% (NBK603710; PMC10108140).
  • Clinical setting prevalence: Specialized eating-disorder services 5–22.5%; specialized pediatric feeding clinics 32–64% (highest of any setting); general pediatric outpatient/inpatient services 3–7.2%.
  • Incidence: 2.02 per 100,000 children/adolescents (ages 5–18) per Canadian national pediatric surveillance (Katzman et al. 2021, cited PMC10108140).

Genetic Architecture (not classical Mendelian)

  • Inheritance pattern: Complex/polygenic — not Mendelian (AD/AR/X-linked/mitochondrial). Twin-study heritability of 0.79 places ARFID's genetic architecture closer to neurodevelopmental disorders (ASD, ADHD) than to classic single-gene conditions (PMID 36723946).
  • Penetrance/expressivity: Not applicable in the classical sense; expressivity is highly variable across the three symptom-driver subtypes and modified by comorbid ASD/anxiety.
  • Genetic anticipation, germline mosaicism, founder effects, consanguinity: Not applicable/not reported — none of these classical Mendelian-genetics concepts have documented relevance to ARFID.
  • Carrier frequency: Not applicable (polygenic trait, not a discrete carrier state).

Population Demographics

  • Sex ratio: More balanced than other eating disorders; clinical samples show 21–50% male (versus the strong female skew of AN/BN); some pediatric ASD-comorbid samples approach parity.
  • Age distribution: Peak clinical presentation in later childhood/early adolescence (mean 11.1–14.6 years), though a documented developmental peak of sub-diagnostic selective eating exists in early childhood (ages 2–6) that is normative and distinct from clinical ARFID.
  • Geographic/ethnic variation: Limited data; prevalence estimates vary substantially by country/instrument (e.g., Taiwan 0.3–0.5% vs. Portugal 15.5% in school samples), likely reflecting screening-tool and cultural differences rather than confirmed true prevalence differences (PMC10108140).
  • Comorbidity-driven subpopulations: ASD populations show markedly elevated ARFID prevalence — pooled meta-analytic estimate ~16.27% ARFID prevalence among individuals with ASD, and ~11.41% ASD prevalence among individuals with ARFID (2025 meta-analysis, PMC11891632); anxiety disorder comorbidity 9.1–72% (up to ~71% in some cohorts), with generalized anxiety disorder most common.

10. Diagnostics

Clinical Criteria (Primary Diagnostic Method)

DSM-5 criteria (four-part, per NBK603710): - Criterion A: Eating/feeding disturbance manifest as persistent failure to meet nutritional/energy needs, evidenced by ≥1 of: significant weight loss (or failure to achieve expected growth in children); significant nutritional deficiency; dependence on enteral feeding/oral nutritional supplements; marked interference with psychosocial functioning. - Criterion B: Not better explained by lack of available food or culturally sanctioned practice. - Criterion C: Not occurring exclusively during AN/BN, and no evidence of disturbed body-weight/shape experience. - Criterion D: Not attributable to a concurrent medical condition or better explained by another mental disorder (or, if occurring in the context of another condition, exceeds what would routinely be expected and warrants independent clinical attention).

ICD-11 (6B83) criteria are conceptually parallel: avoidance/restriction resulting in (1) insufficient quantity/variety to meet needs → weight loss, nutritional deficiency, supplement/tube dependence, or physical-health impact; or (2) significant functional impairment; explicitly not motivated by weight/shape concerns.

Structured Diagnostic Instruments

  • PARDI (Pica, ARFID, and Rumination Disorder Interview): Clinician-administered semi-structured interview; subscale internal consistency: sensory sensitivity α=0.77, lack of interest α=0.89, fear of aversive consequences α=0.79, overall severity α=0.89; diagnostic Cohen's κ=0.75 (PMID 38849953).
  • PARDI-AR-Q (self/parent-report questionnaire version): Correctly identified ~90% of ARFID cases against DSM-5 criteria regardless of subtype profile; includes a severity-of-impact scale and diagnostic algorithm, distinguishing it from NIAS.
  • NIAS (Nine-Item ARFID Screen): Brief adult self-report; three 3-item subscales ("picky eating," "fear," "low appetite"); total scale α=0.84, ω=0.90; useful as a symptom-severity estimator but not validated as a standalone diagnostic tool against clinical interview.
  • EDA-5 (Eating Disorder Assessment for DSM-5) and SCID-5: General structured clinical interviews with ARFID modules.
  • EDE-ARFID module: 22-item, 7-point Likert; α=0.81–0.94.
  • EDY-Q: 14-item self-report for ages 8–13, 12 ARFID-relevant items, α=0.62 (lower reliability, pediatric self-report).

Laboratory/Ancillary Workup (supportive, not diagnostic)

CBC, comprehensive metabolic panel with LFTs, thyroid function, vitamin/mineral panel (notably B12, vitamin K, iron, zinc, folate — often deficient given reduced animal-protein/vegetable intake), celiac screening, and (in females) LH/FSH/estradiol for amenorrhea workup; ECG for bradycardia/arrhythmia risk in malnourished patients.

Genetic Testing

No genetic test is diagnostic or clinically indicated for idiopathic ARFID; genetic/genomic evaluation is relevant only when ARFID occurs secondary to an identifiable syndromic condition (e.g., ruling out conditions with known feeding-difficulty phenotypes) — this is a differential-diagnosis exclusion exercise rather than an ARFID-confirmatory test.

Differential Diagnosis (per NBM603710)

Anorexia nervosa, bulimia nervosa, GERD, eosinophilic esophagitis, IBD, food allergy, celiac disease, autism spectrum disorder, anxiety disorders/OCD, major depressive disorder, PTSD, ADHD, pica, rumination disorder, endocrine disorders (Addison disease, hypothyroidism), and structural oropharyngeal abnormalities.

Screening

No population-level newborn or universal screening program exists. The key clinical screening challenge is distinguishing pathological ARFID from developmentally normative early-childhood "picky eating," which is common under age 6–7 and typically resolves without intervention (PMC12736178).

11. Outcome/Prognosis

  • Mortality: Not separately quantified in the literature reviewed here; medical complications of severe malnutrition (cardiac arrhythmia, refeeding syndrome) carry recognized mortality risk analogous to severe anorexia nervosa, but ARFID-specific mortality/case-fatality statistics were not identified in this search and should be treated as a data gap.
  • Persistence/course: A prospective 2-year longitudinal study (PMID 38718975) found ARFID is not a transient developmental phase — nearly half of patients continued to meet full diagnostic criteria at 2-year follow-up, with only a minority achieving full remission; 3% showed diagnostic shift to anorexia nervosa over the same period.
  • Predictors of persistence vs. remission: Greater sensory-sensitivity and lack-of-interest severity predicted persistence at year 1; greater fear-of-aversive-consequences severity predicted remission at year 2 — the three symptom drivers thus carry distinct prognostic implications and may warrant differentiated treatment planning.
  • Adult treatment outcomes: Adults with ARFID at a tertiary eating-disorders program progressed through inpatient treatment more slowly and achieved less favorable weight outcomes at discharge than matched anorexia-nervosa patients, though completion rates and functional-impairment improvement were reported as good overall, with significant BMI improvement among those admitted underweight (PMC10807227).
  • Bone health: A narrative review (PMC10031860) documents compromised bone mineral density as a recognized long-term morbidity, paralleling AN-associated osteopenia/osteoporosis risk.
  • Course-shift risk: A minority of ARFID cases develop overvaluation of shape/weight over time, effectively transitioning toward an AN-like clinical picture (PMC11067077) — an important longitudinal monitoring consideration.
  • Quality of life: Chronic course, longer pre-diagnosis illness duration, and high anxiety/social-impairment comorbidity together produce sustained functional and psychosocial burden; standardized disease-specific QoL instrument data (e.g., EQ-5D) specific to ARFID were not identified in this search.

12. Treatment

Pharmacotherapy (all off-label; no FDA-approved medication exists for ARFID)

  • Mirtazapine: H1-histaminergic antagonism drives an orexigenic (appetite-stimulating) and anxiolytic effect; also addresses visceral hypersensitivity/nausea. Gray et al. (retrospective study, 14 patients) found a statistically significant increase in weekly BMI-change rate after starting mirtazapine (0.10 → 0.23 BMI-units/week) (PMID 38849953). MAXO/NCIT: Pharmacotherapy (NCIT:C15986); therapeutic_agent mirtazapine (CHEBI:6980, verify exact ID at curation time).
  • Cyproheptadine: Antihistamine/serotonin antagonist used off-label as an appetite stimulant, primarily in case series.
  • Olanzapine: Second-generation antipsychotic; blocks histaminergic/serotonergic receptors in the lateral hypothalamus, reducing cognitive rigidity about food and stimulating appetite/weight gain; case-series evidence also suggests benefit for associated anxiety/depressive symptoms.
  • Buspirone: Anxiolytic used specifically for fear-of-aversive-consequences (e.g., choking-phobia) presentations; case-report-level evidence.
  • D-cycloserine: NMDA partial agonist studied as an exposure-therapy augmentation agent for food aversions.
  • Explicit evidence gap: "There are no randomized, double-blind, placebo-controlled trials of any psychopharmacological agent for ARFID" (multiple sources concur); all pharmacological evidence is case-series/retrospective-cohort level.

Psychotherapy / Behavioral Interventions

  • CBT-AR (Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder): Developed for ages 10+; centers on repeated food exposure under inhibitory-learning principles rather than the body-image/weight-cognition focus used in CBT for AN/BN. Open-trial evidence (Dumont et al. 2019; Thomas et al. 2020, 2021) shows significant reductions in PARDI severity scores, increased dietary variety, and weight gain in underweight patients; tube feeding was discontinued in 6/11 patients in one pilot. Notably, "daily exposure to the visual, olfactory, and harmless consequences of consuming food alone does not appear to reduce avoidant behaviour" as robustly as in classic anxiety-disorder exposure therapy — suggesting ARFID-specific exposure protocols require adaptation, not direct transplantation from anxiety-disorder CBT.
  • FBT-ARFID (Family-Based Treatment, adapted from FBT for AN/BN): Trains parents/caregivers as agents of behavioral change; pilot data (Lock et al. 2018 case series; ongoing RCT randomizing ~100 children ages 6–12 to FBT-ARFID vs. Psychoeducation/Motivation Therapy, PMID 36460266) suggest efficacy, with improved parental self-efficacy proposed as the treatment mechanism.
  • SPACE (Supportive Parenting for Anxious Childhood Emotions): Caregiver-focused intervention targeting reduction of parental accommodation behaviors that perpetuate avoidance.

Nutritional Rehabilitation

Core and often first-line: gradual expansion of accepted-food range, regular meal structure, close growth monitoring (pediatric), and — more frequently than in AN — enteral/nasogastric tube feeding or oral nutritional supplementation in severe malnutrition, with careful titration to avoid iatrogenic reinforcement of oral-food avoidance and monitoring for refeeding syndrome.

Hospitalization Criteria (APA)

BMI <75% of median for age/sex; dehydration; abnormal electrolytes; ECG abnormalities; bradycardia (<50 bpm daytime/<45 bpm nocturnal); hypotension (<90/45 mmHg); hypothermia (<96°F); orthostatic pulse increase (>30 bpm adults/>40 bpm adolescents); growth impairment; failed outpatient treatment; concurrent psychiatric/medical complications.

Experimental/Ongoing Trials

  • NCT (protocol PMID 36460266): FBT-ARFID vs. Psychoeducational Motivation Therapy RCT, ages 6–12.
  • Weighted-blanket intervention trial for food-related anxiety in pediatric ARFID (NCT06420232) — a novel sensory/behavioral adjunct approach.
  • CBT-AR open trial at Massachusetts General Hospital.

Suggested MAXO/treatment-ontology mappings for a dismech entry

  • MAXO:0000950 supportive care (nutritional rehabilitation/monitoring)
  • NCIT:C15986 Pharmacotherapy (mirtazapine, cyproheptadine, olanzapine, buspirone — each via therapeutic_agent)
  • Behavioral/psychotherapy treatment_term candidates: CBT-AR and FBT-ARFID would map to a psychotherapy/behavioral-counseling MAXO term (verify exact MAXO ID at curation time, e.g., analogous to MAXO:0000077 behavioral counseling) with therapeutic_modality: BEHAVIORAL.

13. Prevention

  • Primary prevention: No established primary-prevention strategy exists; the literature explicitly states, "There's no known way to prevent avoidant/restrictive food intake disorder" (Cleveland Clinic, corroborated by systematic risk-factor review PMC13050801). Given the ~79% heritability estimate, primary prevention in the vaccine/exposure-avoidance sense is not conceptually applicable to this behavioral/neurodevelopmental-spectrum condition.
  • Risk-informed monitoring (quasi-secondary prevention): Because early neurodevelopmental problems (general development, communication/language, attention, social interaction, sleep) predict later ARFID with ~3x elevated odds in the highest-risk percentile, targeted developmental surveillance in high-NDP-risk children is a plausible early-detection strategy, though not yet formalized into guideline-level screening programs.
  • Distinguishing normative from pathological selective eating: Since typical "picky eating" affects a large proportion of children under 6–7 and usually resolves spontaneously, the practical secondary-prevention/early-intervention priority is accurate differentiation (via growth monitoring, nutritional-adequacy assessment, and psychosocial-impairment screening) rather than treating all selective eating as pre-ARFID.
  • Behavioral/feeding-practice interventions: Responsive, low-pressure feeding practices and repeated non-coercive food exposure in toddlerhood are associated with better food-variety outcomes and are the closest analog to a modifiable environmental protective strategy, though rigorous trial evidence for true ARFID-incidence prevention (versus symptom management) is limited.
  • Genetic counseling: Not clinically applicable given the polygenic, non-Mendelian architecture — no risk-percentage counseling framework analogous to single-gene disorders exists.
  • Tertiary prevention: Early diagnosis and treatment initiation (before chronic malnutrition/growth impairment develops) is emphasized throughout the clinical literature as the most actionable "prevention" lever — i.e., preventing progression to severe medical complications (refeeding syndrome, growth failure, osteopenia) rather than preventing the underlying disorder itself.

14. Other Species / Natural Disease

  • Taxonomy: No naturally occurring ARFID-equivalent disease entity has been characterized in non-human species in the veterinary/OMIA literature identified here. Feeding selectivity/food neophobia occurs across many species as a normal behavioral trait (evolutionarily conserved anti-poisoning strategy) but is not modeled as a spontaneous "disease" analog to human ARFID.
  • Breed-specific: Not applicable — no VBO-catalogued breed-specific ARFID-like condition was identified.
  • Comparative biology: Food neophobia (reluctance to eat novel foods) is a well-studied, evolutionarily conserved behavior in rodents and birds, studied largely in the context of pest-control/bait-avoidance research rather than as a disease model, but conceptually informs the human ARFID sensory/neophobia construct (ResearchGate: "Exploitable characteristics of neophobia and food aversions for improvements in rodent and bird control").
  • Zoonotic potential: Not applicable — ARFID is not an infectious or transmissible condition.

15. Model Organisms

  • No dedicated, validated ARFID animal model exists as of this literature search — this is an explicit and acknowledged gap in the field.
  • Closest available model — Conditioned Taste Aversion (CTA) in rodents: A systematic review (ScienceDirect, 2023) proposes rodent CTA paradigms as "a potential animal model of pediatric feeding disorder and ARFID," reasoning that CTA — in which an animal learns to avoid a taste/food previously paired with illness — parallels the fear-of-aversive-consequences ARFID subtype. The review notes CTA "has been observed in humans and parallels many of the characteristics of rodent CTA," and evaluates pharmacological agents shown to reduce CTA in rodents as candidate translational treatments.
  • Applications: CTA models are proposed to probe neural mechanisms maintaining food-specific fear/avoidance and to screen candidate pharmacological interventions (e.g., agents that reduce learned aversion), but they model only the fear-driven subtype, not the sensory-sensitivity or inappetence subtypes.
  • Limitations: No rodent, zebrafish, Drosophila, C. elegans, or iPSC/organoid model captures the full multi-subtype human ARFID phenotype (sensory hyperresponsiveness + appetite dysregulation + fear conditioning + the psychosocial/functional-impairment criterion); given the polygenic, non-Mendelian genetic architecture, no knockout/transgenic genetic model is currently justified by a specific causal gene.
  • Resources: No MGI, RGD, ZFIN, or IMPC entries specific to "ARFID" exist; relevant rodent feeding-behavior/appetite genetic models (e.g., ghrelin, leptin, hypothalamic circuit knockouts) are general appetite-regulation models, not ARFID-specific, and any use for dismech curation purposes should draw the distinction between "informative appetite-circuit model" and "ARFID disease model" carefully.

Summary of Key Ontology Term Recommendations for KB Curation

Category Term suggestions (verify via OAK before use)
MONDO Not confirmed in this search — verify via runoak -i sqlite:obo:mondo search
HP (phenotypes) HP:0011968 Feeding difficulties; HP:0001508 Failure to thrive; HP:0004322 Short stature; HP:0000786 Secondary amenorrhea; HP:0001903 Anemia; HP:0001662 Bradycardia; HP:0000939 Osteopenia; HP:0000823 Delayed puberty; HP:0000739 Anxiety
GO (biological processes) GO:0007631 feeding behavior; GO:0050909 sensory perception of taste; GO:0032099/GO:0032100 regulation of appetite; GO:0001662 behavioral fear response
CL (cell types) CL:0000209 taste receptor cell; CL:0000164 enteroendocrine cell; CL:0000540 neuron
UBERON UBERON:0001876 amygdala; UBERON:0002018 insular cortex; UBERON:0001870 frontal cortex; UBERON:0000955 brain
MAXO/NCIT (treatments) NCIT:C15986 Pharmacotherapy (+ therapeutic_agent: mirtazapine, cyproheptadine, olanzapine, buspirone); behavioral-counseling term for CBT-AR/FBT-ARFID; MAXO:0000950 supportive care

Key Citations

  • Dinkler L, et al. Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years. JAMA Psychiatry. 2023;80(3):260-269. PMID: 36723946
  • Fonseca NK, et al. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. J Eat Disord. 2024;12:74. PMID: 38849953
  • Bourne L, et al. What do we know about the epidemiology of avoidant/restrictive food intake disorder in children and adolescents? A systematic review. PMID: 36527163
  • Neural Response to Food Cues in Avoidant/Restrictive Food Intake Disorder. PMID: 39964683
  • Sader M, et al. Neural correlates of children with avoidant restrictive food intake disorder symptoms: large-scale neuroanatomical analysis. J Child Psychol Psychiatry. PMID: 39623765
  • Prospective 2-Year Course and Predictors of Outcome in ARFID. PMID: 38718975
  • ARFID Genes and Environment (ARFID-GEN): study protocol. BMC Psychiatry. PMID: 37990202
  • NBK603710 — Avoidant Restrictive Food Intake Disorder, StatPearls (NCBI Bookshelf)
  • Sader M, et al. The Co-Occurrence of Autism and ARFID: A Prevalence-Based Meta-Analysis. Int J Eat Disord. PMC11891632
  • ICD-11 6B83 Avoidant-restrictive food intake disorder — findacode.com
  • Risk factors for avoidant/restrictive food intake disorder in children: A systematic review. J Pediatr Gastroenterol Nutr. 2026. PMC13050801
  • Systematic review of pharmacological treatments that reduce conditioned taste aversions in rodents: A potential animal model of pediatric feeding disorder and ARFID. ScienceDirect
Falcon ▸
Avoidant/Restrictive Food Intake Disorder (ARFID): Disease Characteristics Report
Edison Scientific Literature 38 citations 2026-07-29T23:20:30.857107

Avoidant/Restrictive Food Intake Disorder (ARFID): Disease Characteristics Report

Executive summary

Avoidant/restrictive food intake disorder (ARFID) is a psychiatric feeding/eating disorder in which persistent restriction of food quantity or variety causes clinically important nutritional, growth, medical, supplement-dependence, or psychosocial consequences without restriction being driven primarily by weight or shape concerns. The three canonical presentations—sensory sensitivity, lack of interest/low appetite, and fear of aversive consequences—are dimensions that frequently overlap rather than mutually exclusive subtypes. In a 2024 UK/Republic of Ireland surveillance study of 319 clinically diagnosed young people, the largest class was a combined sensory/lack-of-interest presentation (38.2%). (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

Current understanding favors a multifactorial developmental disorder involving sensory processing, appetite/homeostatic signaling, fear learning/negative valence, neurodevelopmental vulnerability, medical experiences, and family/environmental reinforcement. No monogenic cause, pathogenic variant, diagnostic molecular biomarker, or disease-specific drug has been established. Treatment is therefore individualized and multidisciplinary, with nutritional rehabilitation plus exposure-based cognitive-behavioral therapy or family-based treatment providing the most promising evidence. Most efficacy evidence nevertheless remains from case series, uncontrolled studies, and recently completed trials whose definitive results are not yet widely published. (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 4-6)

The following table summarizes the highest-yield evidence.

Domain Best current evidence Evidence strength/limitations Key source metadata
Definition & identifiers ARFID is a DSM-5/ICD-11 feeding/eating disorder defined by persistent restriction/avoidance causing inability to meet nutritional/energy needs with weight/growth effects, nutritional deficiency, supplement/enteral dependence, or psychosocial impairment, without body-image disturbance; MeSH term present in ClinicalTrials derived metadata: “Avoidant Restrictive Food Intake Disorder” (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2, NCT06110806 chunk 2) Strong consensus on nosology; MONDO/OMIM not established in retrieved evidence; mostly disease-level aggregated resources rather than EHR-derived data Fonseca et al., J Eat Disord 2024, published Jun 2024, DOI: https://doi.org/10.1186/s40337-024-01021-z; Sanchez-Cerezo et al., eClinicalMedicine 2024, Feb 2024, DOI: https://doi.org/10.1016/j.eclinm.2024.102440; ClinicalTrials.gov NCT06110806 posted 2023-11-01 (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2, NCT06110806 chunk 2)
Diagnostic presentations & 2024 latent classes Core presentations: sensory sensitivity, lack of interest/low appetite, fear of aversive consequences; 2024 UK/ROI surveillance LCA of 319 cases identified 4 classes: Fear 7.2% (n=23), Lack of Interest 25.1% (n=80), Sensory 29.5% (n=94), Combined 38.2% (n=122) (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2) Strongest recent empirical subtype evidence in pediatric secondary care; may not generalize to adults/community samples Sanchez-Cerezo et al., eClinicalMedicine 2024, Feb 2024, DOI above; Fonseca et al. 2024 review (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)
Epidemiology Recent review summarizes prevalence estimates around 0.5–5% in children/adults; pediatric surveillance incidence in Canada reported as 2.02 per 100,000 ages 5–18 years (95% CI 1.76–2.31); mean age often 11.1–14.6 years; males comprise roughly 21–50% in clinical samples (fonseca2024avoidantrestrictivefood pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3) Estimates highly heterogeneous by setting and method; no robust incidence data for adults in retrieved evidence Fonseca et al., J Eat Disord 2024; Sanchez-Cerezo et al., eClinicalMedicine 2024 (fonseca2024avoidantrestrictivefood pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)
Etiology, risk factors & comorbidity Multifactorial model: predisposing neurodevelopmental/medical factors (ASD, ADHD, GI/neurologic disorders, food allergy), precipitating events (vomiting, choking, abdominal pain, bullying, bereavement, medication start), and perpetuating family/behavioral factors; anxiety disorders common (9.1–72%); ASD frequently co-occurs, especially sensory/combined presentations (fonseca2024avoidantrestrictivefood pages 4-6, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3, nocerino2024developmentandmanagement pages 4-6) Mostly observational and review-level evidence; causal direction often unclear; protective factors not well established in retrieved literature Fonseca et al. 2024; Sanchez-Cerezo et al. 2024; Nocerino et al., Nutrients 2024, Sep 2024, DOI: https://doi.org/10.3390/nu16173034 (fonseca2024avoidantrestrictivefood pages 4-6, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3, nocerino2024developmentandmanagement pages 4-6)
Genetics No monogenic cause established. Review evidence cites a Swedish twin study showing important genetic contribution/high heritability; one review notes a reported locus near ZSWIM6, but this was not primary-source validated in retrieved accessible texts. Large-scale ARFID genetics infrastructure is expanding via EDGI2 (tomaszek2025unravelingtheconnections pages 2-4) Genetic architecture remains early-stage; retrieved evidence does not support causal genes, ClinVar variants, or penetrance estimates for ARFID Tomaszek et al., Nutrients 2025, Jan 2025, DOI: https://doi.org/10.3390/nu17030486; EDGI2 protocol, BMC Psychiatry 2025, DOI: https://doi.org/10.1186/s12888-025-06777-5 (not context-cited in table cells beyond accessible ID) (tomaszek2025unravelingtheconnections pages 2-4)
Mechanisms / pathophysiology Best current model is 3-dimensional: altered sensory processing, appetite/homeostatic dysregulation, and negative valence/fear circuitry. Hypothesized regions/signals include insula, orbitofrontal cortex, hypothalamus, amygdala, anterior cingulate, and gut-brain hormones (ghrelin, PYY, CCK, GLP-1). ARFID severity is linked to lower anticipatory pleasure, especially lack-of-interest phenotype; depression partly explains anhedonia findings (fonseca2024avoidantrestrictivefood pages 1-2, fonseca2024avoidantrestrictivefood pages 6-7, dolan2023anticipatoryandconsummatory pages 1-2, dolan2023anticipatoryandconsummatory pages 8-9) Human evidence is still limited and partly hypothesis-driven; little validated omics or pathway-level molecular profiling; no disease-specific GO/CL mappings directly established in retrieved sources Fonseca et al. 2024 review; Dolan et al., J Eat Disord 2023, Nov 2023, DOI: https://doi.org/10.1186/s40337-023-00921-w (fonseca2024avoidantrestrictivefood pages 1-2, fonseca2024avoidantrestrictivefood pages 6-7, dolan2023anticipatoryandconsummatory pages 1-2, dolan2023anticipatoryandconsummatory pages 8-9)
Phenotypes, complications & QoL Complications include malnutrition, growth delay, enteral dependence, hospitalization, hypokalemia, fatigue, lethargy, presyncope, constipation, cold intolerance, hypothermia, dry skin, lanugo, alopecia, bradycardia, orthostatic tachycardia, hypotension, pubertal delay/amenorrhea, lower bone mineral density, oral-motor and speech delays; selective eating also impairs social/emotional development and increases family conflict (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 10-12, nocerino2024developmentandmanagement pages 4-6) Strong clinical face validity; frequency estimates for individual complications are sparse; QoL often described qualitatively rather than with standardized ARFID-specific metrics in retrieved evidence Fonseca et al. 2024; Nocerino et al. 2024 (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 10-12, nocerino2024developmentandmanagement pages 4-6)
Diagnostics & assessment tools Diagnosis remains clinical/DSM-based with exclusion of food unavailability, cultural practice, anorexia/bulimia, and other medical/psychiatric explanations. PARDI has Cronbach α 0.77–0.89 and diagnostic reliability κ=0.75; NIAS total α=0.84, ω=0.90. Trials also use PARDI-AR-Q, EDA-5, labs (thyroid, celiac), anthropometrics, and sometimes fMRI (fonseca2024avoidantrestrictivefood pages 9-10, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4, NCT05954728 chunk 1) Good early psychometrics for screening/interview tools; no universal gold-standard biomarker; diagnostic workup must exclude medical mimics Fonseca et al. 2024; Sanchez-Cerezo et al. 2024; ClinicalTrials.gov NCT05954728 (fonseca2024avoidantrestrictivefood pages 9-10, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4, NCT05954728 chunk 1)
Treatment Multidisciplinary care is standard. Nutritional rehabilitation prioritizes weight restoration and adequacy of macro/micronutrients, with cautious temporary enteral support when necessary. Psychological approaches with best current support are CBT-AR and family-based treatment (FBT-ARFID). Review-level evidence describes significant reductions in ARFID severity, increased food variety, and weight gain in CBT-AR proof-of-concept studies; small FBT case series also report weight gain and reduced anxiety (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 10-12, fonseca2024avoidantrestrictivefood pages 12-13) Evidence base still dominated by case series, pilot studies, and nonrandomized designs; no FDA-approved medication for ARFID Fonseca et al. 2024, DOI above (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 10-12, fonseca2024avoidantrestrictivefood pages 12-13)
Pharmacotherapy Adjunctive medications reported include olanzapine, mirtazapine, fluoxetine, cyproheptadine, and buspirone. Review cites mirtazapine-associated BMI change rising from 0.10 to 0.23/week after initiation and notes olanzapine may improve appetite, anxiety, and rigidity; all evidence is case-based/small series (fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 13-14) Very low-certainty evidence; no approved drug and no definitive randomized placebo-controlled data in retrieved sources Fonseca et al., J Eat Disord 2024 (fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 13-14)
Clinical trials / implementation Key active/completed trials include: Stanford FBT-ARFID efficacy/mechanism RCT vs non-specific care, ages 6–12, n=98, completed (NCT04450771); earlier Stanford crossover FBT feasibility trial, ages 5–12, n=28, completed (NCT03778216); MGH COUNTERACT RCT of CBT-AR vs nutrition counseling, ages 10–18, n=53, completed (NCT05954728); MGH CBT-AR pilot single-group, ages 10–65, n=35, completed (NCT02963220); Mount Sinai MBIE family-based interoceptive exposure, actual n=12, terminated for risk-mitigation-plan disagreement (NCT06110806) (NCT04450771 chunk 1, NCT03778216 chunk 1, NCT05954728 chunk 1, NCT02963220 chunk 1, NCT06110806 chunk 1) Strong signal of growing implementation research; many results still pending publication or limited to protocol/trial registry detail ClinicalTrials.gov: NCT04450771, NCT03778216, NCT05954728, NCT02963220, NCT06110806 (NCT04450771 chunk 1, NCT03778216 chunk 1, NCT05954728 chunk 1, NCT02963220 chunk 1, NCT06110806 chunk 1)
Natural disease in other species / models No recognized naturally occurring veterinary ARFID entity or validated full-disorder animal model was identified in retrieved evidence; at most, component traits such as sensory aversion, appetite regulation, fear conditioning, or gut-brain signaling can be modeled separately Important negative finding; avoids over-interpreting feeding phenotypes in animals as DSM-defined ARFID No disease-specific comparative biology source identified in retrieved ARFID literature (fonseca2024avoidantrestrictivefood pages 1-2, fonseca2024avoidantrestrictivefood pages 14-15)

Table: This compact table summarizes the best available current evidence for avoidant/restrictive food intake disorder across definition, subtypes, epidemiology, mechanisms, diagnostics, treatment, and trials. It emphasizes where evidence is strongest and where important limitations remain.

1. Disease information

Definition and scope

DSM-5 introduced ARFID in 2013 as the successor to and expansion of “feeding disorder of infancy or early childhood.” It includes children, adolescents, and adults. Criterion A requires an eating/feeding disturbance with persistent failure to meet nutritional or energy needs and at least one of: significant weight loss or failure to grow appropriately; significant nutritional deficiency; dependence on oral supplements or enteral feeding; or marked interference with psychosocial functioning. Restriction cannot be adequately explained by unavailable food or culturally sanctioned practice, cannot occur exclusively during anorexia nervosa or bulimia nervosa, and is not driven by body-weight or shape disturbance. If another medical or psychiatric disorder is present, restriction must exceed what that condition ordinarily explains and independently require clinical attention. (fonseca2024avoidantrestrictivefood pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

Direct abstract wording: Sanchez-Cerezo et al. described ARFID as “persistent disturbance in feeding or eating” causing inability to meet nutritional/energy needs, while emphasizing that it “is not associated with concerns about gaining weight nor with a preoccupation about body weight, shape, or size.” The study was published in eClinicalMedicine in February 2024; DOI: https://doi.org/10.1016/j.eclinm.2024.102440. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

Identifiers and synonyms

  • MeSH: Avoidant Restrictive Food Intake Disorder, D000080146. (NCT06110806 chunk 2)
  • ICD-11: ARFID is recognized as a feeding or eating disorder; the commonly used ICD-11 code is 6B83.
  • ICD-10-CM: F50.82, Avoidant/restrictive food intake disorder.
  • DSM-5/DSM-5-TR: Avoidant/restrictive food intake disorder.
  • MONDO: A stable MONDO identifier was not verified in the retrieved authoritative material; populate only after direct confirmation from the current MONDO release.
  • OMIM/Orphanet: No disease-specific entry is expected because ARFID is neither an established Mendelian disease nor conventionally classified as a rare genetic disorder.
  • Synonyms: avoidant/restrictive food intake disorder; avoidant restrictive food intake disorder; ARFID; historically, selective eating disorder. “Picky eating,” food neophobia, infantile anorexia, and pediatric feeding disorder overlap clinically but are not synonyms unless full diagnostic criteria are met. (fonseca2024avoidantrestrictivefood pages 1-2, nocerino2024developmentandmanagement pages 4-6)

The evidence summarized here is aggregated disease-level literature and trial-registry data, not individual EHR-derived patient data. Individual case reports and clinical cohorts contribute to treatment evidence but should not be treated as population estimates.

2. Etiology, risk, protective factors, and gene–environment interaction

Causal framework

ARFID has no single necessary or sufficient cause. A useful model separates:

  1. Predisposing factors: sensory hyperresponsivity, anxiety temperament, ASD, ADHD, GI or neurologic disease, food allergy, and possibly inherited appetite or taste sensitivity.
  2. Precipitating factors: choking, vomiting, abdominal pain, allergic reaction or fear of one, painful oral/GI procedures, medication initiation, bullying, bereavement, or other stressful events.
  3. Perpetuating factors: conditioned fear and avoidance, relief following food refusal, provision of only preferred foods, reduced exposure to novel foods, parental distress or coercive mealtime interactions, malnutrition-associated early satiety/GI dysmotility, and social withdrawal. In one retrospective cohort summarized by the 2024 review, 71.4% reported an identifiable trigger. (fonseca2024avoidantrestrictivefood pages 4-6)

Food allergy illustrates a plausible gene–environment/medical–behavioral pathway: a genuine adverse reaction produces heightened threat expectancy; avoidance generalizes beyond the allergen to tolerated foods; parental anxiety and limited dietary exposure reinforce fear; and reduced variety produces deficiency and psychosocial impairment. This is clinical observational evidence, not proof that allergy independently causes ARFID. (nocerino2024developmentandmanagement pages 4-6)

Genetic risk

A Swedish twin study published in 2023 reported substantial heritability for a broad pediatric ARFID phenotype, with nonshared environmental effects also contributing. However, the broad phenotype did not fully represent all fear-of-aversive-consequence cases, so it should not be interpreted as the heritability of DSM-5 ARFID in its entirety. Recent reviews mention a chromosome-5 signal near ZSWIM6, but a causal locus or clinically actionable variant has not been validated in the retrieved primary evidence. (tomaszek2025unravelingtheconnections pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10)

Accordingly:

  • Causal genes/pathogenic variants: none established.
  • Inheritance: complex, multifactorial/polygenic—not Mendelian.
  • Penetrance, carrier frequency, anticipation, founder effects, germline mosaicism: not applicable or unknown.
  • ClinVar/ClinGen testing: no ARFID-specific clinically validated gene or panel.
  • Modifier genes/epigenetics: no replicated ARFID-specific modifiers or epigenetic signature.
  • Somatic variants/chromosomal abnormalities: not features of idiopathic ARFID.

Environmental and lifestyle risks

There is no established toxin, pollutant, radiation, occupational exposure, infection, smoking, alcohol, or exercise exposure that specifically causes ARFID. Relevant “environmental” factors are mainly developmental and experiential: limited early food exposure, adverse feeding experiences, food insecurity as a diagnostic alternative rather than ARFID, family accommodation, and culturally mediated food availability. Food restriction due solely to poverty, famine, neglect, religious observance, or another culturally sanctioned practice excludes ARFID. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

Protective factors

No genetic protective variant is established. Plausible but incompletely tested protective factors include responsive feeding, repeated noncoercive exposure to varied foods, prompt treatment of pain/allergy/GI disease, accurate allergy education, predictable meals, avoidance of unnecessary elimination diets, parental self-efficacy, and early multidisciplinary intervention. These should be annotated as expert-informed prevention strategies, not proven primary-prevention effects.

3. Phenotypes

Core behavioral phenotypes

  1. Sensory sensitivity: rejection based on texture, taste, smell, temperature, color, appearance, brand, or foods touching. It often begins early and may remain stable without intervention. Suggested HPO concepts: Feeding difficulties (HP:0011968), abnormal eating behavior, and sensory hypersensitivity; exact current HPO IDs should be validated before ingestion.
  2. Lack of interest/low appetite: little hunger, early satiety, forgetting to eat, small bites, slow or prolonged meals, and low anticipatory reward. Suggested HPO: Poor appetite (HP:0004396) and feeding difficulties.
  3. Fear of aversive consequences: acute or subacute avoidance following choking, vomiting, pain, allergic reaction, or invasive procedures; fear may generalize to entire food groups or settings. Suggested HPO: feeding difficulties, anxiety, vomiting, dysphagia/choking where actually present.
  4. Mixed/combined presentation: common and clinically important. In 319 UK/ROI cases aged 5–18, classes were Fear 7.2% (23), Lack of Interest 25.1% (80), Sensory 29.5% (94), and Combined 38.2% (122). Younger age, male sex, eating distress, weight loss, and ASD distinguished class membership. (sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10, sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

A Swiss school study summarized in the 2024 paper found ARFID features in 3.2%; among these children, 39% reported lack of interest, 60% sensory sensitivity, 15% fear, and 15% multiple presentations. Because dimensions overlap, percentages need not sum to 100%. (sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

Physical and laboratory phenotypes

Depending on diet and severity, findings include weight loss or faltering growth, underweight, anemia, hypokalemia, micronutrient deficiencies, fatigue, lethargy, impaired memory, presyncope, constipation, cold intolerance, hypothermia, dry skin, lanugo, alopecia, bradycardia, orthostatic tachycardia/hypotension, delayed puberty, amenorrhea, and low bone mineral density. Oral-motor or speech delay may occur when children have had little experience chewing complex textures. (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 10-12)

Deficiencies depend more on foods omitted than on BMI. Restriction of grains risks inadequate carbohydrate and fiber; animal products/dairy/legumes can reduce protein, riboflavin, B12, iron, selenium, and zinc; fish avoidance can reduce vitamin D and omega-3 intake; fruit/vegetable avoidance can reduce vitamin C and folate; and broad fat restriction can reduce vitamins A, D, E, and K. Normal or high body weight therefore does not exclude significant nutritional deficiency. (fonseca2024avoidantrestrictivefood pages 12-13)

Psychosocial and quality-of-life phenotypes

Patients may be unable to eat at school, restaurants, celebrations, or with peers; may carry preferred foods everywhere; experience tantrums or severe distress; and have excessively long meals, school impairment, restricted peer relationships, and family conflict. These impairments can satisfy Criterion A even without underweight. Standardized ARFID-specific quality-of-life data remain sparse; trials use measures such as the Clinical Impairment Assessment, SF-36, Strengths and Difficulties Questionnaire, and pediatric generic quality-of-life scales. (fonseca2024avoidantrestrictivefood pages 10-12, sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4, NCT04450771 chunk 2)

4. Genetic and molecular information

No causal gene, HGNC-annotated pathogenic variant, ACMG/AMP classification, allele frequency, protein loss/gain of function, or diagnostic structural variant is established for ARFID. WES, WGS, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not routine ARFID tests. They are appropriate only when syndromic features, intellectual disability, congenital anomalies, neurologic findings, or another suspected genetic disorder independently warrant investigation.

Molecular profiling is preliminary. There is no replicated disease-defining transcriptomic, proteomic, metabolomic, lipidomic, epigenomic, single-cell, spatial-transcriptomic, multi-omic, or CRISPR-screen signature. This negative annotation is important: ARFID is currently diagnosed phenotypically, not molecularly.

5. Environmental information

No infectious agent or zoonotic transmission is implicated. GI disease, food allergy, pain, vomiting and choking are medical/environmental triggers rather than infectious etiologies. Restrictive diets prescribed for legitimate disease can become disproportionate and impairing; clinicians should distinguish medically necessary avoidance from generalized fear and restriction exceeding medical requirements. In GI populations, reported ARFID-screen positivity varies substantially—approximately 40% in some disorder-of-gut–brain-interaction samples, 17% in IBD, and 6–24% in neurogastroenterology settings—although these figures are not general-population prevalence and may be inflated by symptom overlap or screening methods. (che2025avoidantrestrictivefoodintake pages 13-15)

6. Mechanism and pathophysiology

Three-dimensional model

Sensory pathway: inherited/developmental sensory responsivity and altered integration of taste, smell, touch, and visual food cues → intense aversive experience → selective refusal → reduced exposure and nutritional variety → reinforcement of sensory avoidance. Candidate systems include gustatory/olfactory pathways and insular sensory integration. Taste-receptor variation such as TAS2R-family bitter sensitivity is biologically plausible but not an established ARFID cause. (fonseca2024avoidantrestrictivefood pages 4-6, fonseca2024avoidantrestrictivefood pages 6-7)

Homeostatic/appetite pathway: reduced hunger, early satiation, or low food reward → inadequate meal initiation/maintenance → low intake and growth/weight consequences. Candidate structures include hypothalamus, brainstem, insula, and orbitofrontal reward networks. Preliminary endocrine studies have examined ghrelin, peptide YY, cholecystokinin, and GLP-1; findings are inconsistent and may reflect malnutrition rather than upstream disease. A cited study found higher fasting CCK in full/subthreshold ARFID than controls after adjustment, while low-weight ARFID showed lower meal-related total ghrelin than anorexia nervosa. These remain research findings, not biomarkers. (fonseca2024avoidantrestrictivefood pages 6-7)

Negative-valence/fear pathway: adverse event → amygdala/anterior-cingulate threat learning → anticipatory anxiety and autonomic arousal → avoidance → immediate relief (negative reinforcement) → generalization and chronic restriction. Exposure-based therapies directly target this causal loop. (fonseca2024avoidantrestrictivefood pages 6-7)

A 2023 human study of 71 participants aged 10–23 with full/subthreshold ARFID and 33 controls found lower anticipatory and consummatory pleasure, but group differences disappeared after controlling for depression or removing food items. Within ARFID, greater severity and lack-of-interest symptoms remained associated with lower anticipatory pleasure. Thus, generalized anhedonia is not established; food-specific reward and comorbid depression are important confounders. DOI: https://doi.org/10.1186/s40337-023-00921-w, published November 2023. (dolan2023anticipatoryandconsummatory pages 1-2, dolan2023anticipatoryandconsummatory pages 8-9)

Suggested ontology annotations, treated as mechanistic hypotheses rather than proven disease pathways:

  • GO biological processes: sensory perception of taste; sensory perception of smell; feeding behavior; regulation of appetite; response to food; associative learning; fear response; energy homeostasis.
  • Cell Ontology: neuron, sensory neuron, neuroendocrine cell, enteroendocrine cell. No ARFID-specific pathogenic cell type is established.
  • Anatomy: hypothalamus, insular cortex, orbitofrontal cortex, amygdala, anterior cingulate cortex, brainstem, and GI tract.

7. Anatomical structures affected

ARFID is a functional psychiatric/behavioral syndrome, not a focal tissue lesion. The central nervous system mediates sensory, reward, appetite, and threat processes. The oral cavity/pharynx/esophagus/GI tract may be sites of triggering sensations or comorbid disease. Secondary consequences involve bone, endocrine/reproductive, cardiovascular, integumentary, hematologic, and GI systems through malnutrition.

Suggested UBERON mappings include brain (UBERON:0000955), hypothalamus (UBERON:0001898), amygdala, insular cortex, anterior cingulate cortex, oral cavity, pharynx, esophagus, stomach, small intestine, and bone tissue. There is no expected lateralization. No specific organelle or GO cellular-component defect is known.

8. Temporal development

Onset is commonly pediatric and may be insidious for sensory/lack-of-interest presentations or abrupt after an aversive event for fear-based ARFID. Clinical cohorts often have mean ages around 11.1–14.6 years, but onset can occur in infancy/childhood and persistence into adulthood is well documented. Sensory refusal was more common at younger ages in a 207-patient surveillance sample: 66.7% at 5–9 years, 38.6% at 10–14, and 22.2% at 15–18. (fonseca2024avoidantrestrictivefood pages 2-4, fonseca2024avoidantrestrictivefood pages 6-7)

Course is heterogeneous—stable, progressive, fluctuating, or event-triggered—and no validated disease staging system exists. Compared with anorexia nervosa, ARFID often begins younger and may require longer hospitalization or more enteral support despite similar BMI. Long-term remission, relapse, and transition-to-other-eating-disorder estimates remain inadequately characterized. Comorbidity and entrenched avoidance plausibly predict a more difficult course. (fonseca2024avoidantrestrictivefood pages 10-12, fonseca2024avoidantrestrictivefood pages 14-15)

9. Inheritance and population epidemiology

General-population prevalence is commonly summarized as approximately 0.5–5%, but estimates range from 0.3% to 64% across highly dissimilar community, GI, feeding-clinic, and eating-disorder samples. The only incidence study highlighted in the recent reviews identified 2.02 cases per 100,000 persons aged 5–18 years presenting to pediatricians (95% CI 1.76–2.31). These figures demonstrate methodological heterogeneity rather than true geographic differences. (fonseca2024avoidantrestrictivefood pages 2-4, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

Clinical samples include more boys than classic adolescent eating-disorder cohorts, but ARFID affects all sexes. Reported male proportions range approximately 21–50%. Boys in one surveillance sample had more sensory refusal than girls—51.2% versus 31.5%, p=0.007—whereas fear presentations often skew female. ASD is reported in roughly 13–50% in some clinical literature, while broader reviews report ranges from 8.2% to 54.8%; ascertainment strongly affects these estimates. Anxiety disorders are reported in 9.1–72%. (fonseca2024avoidantrestrictivefood pages 2-4, tomaszek2025unravelingtheconnections pages 2-4, fonseca2024avoidantrestrictivefood pages 4-6, sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3)

There is no established ethnic restriction, endemic region, founder variant, consanguinity effect, carrier state, or population-specific penetrance.

10. Diagnostics

Clinical diagnosis and workup

Diagnosis requires history from patient and caregivers, dietary assessment, growth-chart review, anthropometry, physical examination, psychosocial-functional assessment, and evaluation of body-image motivation. Clinicians should document which Criterion-A consequence is present and characterize all three dimensions rather than forcing one subtype.

Recommended tests are individualized, not diagnostic biomarkers: CBC; electrolytes, renal and hepatic indices; calcium, magnesium and phosphate; glucose; iron/ferritin; B12/folate; vitamin D and other micronutrients suggested by the excluded foods; inflammatory testing where indicated; TSH/free T4; and celiac serology. ECG is appropriate with bradycardia, syncope, electrolyte disturbance, severe malnutrition, or QT-risk medication. Bone-age or DXA assessment may be indicated with growth/puberty delay, prolonged amenorrhea, fractures, or chronic undernutrition. Imaging, endoscopy, swallow study, allergy testing, or motility studies should be driven by clinical indications—not used routinely to “confirm” ARFID. The COUNTERACT trial, for example, required normal thyroid testing and negative celiac screening to exclude medical explanations. (NCT05954728 chunk 1)

Instruments

  • PARDI: semistructured diagnostic/severity interview covering the three profiles; reported internal consistency α=0.77–0.89 and diagnostic reliability κ=0.75.
  • PARDI-AR-Q: 32-item self/parent questionnaire used for dimensional symptom assessment.
  • NIAS: nine-item screen with sensory, appetite, and fear subscales; reported total α=0.84 and ω=0.90. It is a screen, not a stand-alone diagnosis.
  • EDA-5, Eating Disorder Examination ARFID module, and EDY-Q are additional approaches depending on age and setting. (fonseca2024avoidantrestrictivefood pages 9-10, NCT05954728 chunk 1)

Differential diagnosis

Exclude anorexia nervosa/atypical AN and bulimia nervosa; food insecurity or cultural/religious restriction; developmentally typical picky eating; food allergy/celiac disease/eosinophilic esophagitis; inflammatory or structural GI disease; dysphagia and oral-motor disorders; gastroparesis and disorders of gut–brain interaction; endocrine/metabolic disease; malignancy or chronic infection; medication adverse effects; depression-related appetite loss; OCD contamination fears; specific phobia of choking/vomiting; psychosis; ASD-associated selectivity not independently meeting ARFID impairment criteria; rumination disorder; and pica. Another disorder can coexist when restriction is disproportionate and independently impairing. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4)

There is no asymptomatic newborn, carrier, prenatal, or cascade screening program.

11. Outcome and prognosis

ARFID can produce substantial morbidity through malnutrition, growth failure, electrolyte disturbance, cardiovascular instability, delayed puberty, low bone density, dependence on supplements/tubes, and social or educational disability. Severe refeeding carries risk of potentially fatal refeeding syndrome and requires electrolyte and clinical monitoring. (fonseca2024avoidantrestrictivefood pages 9-10, fonseca2024avoidantrestrictivefood pages 12-13)

Disease-specific mortality, five- or ten-year survival, and life-expectancy estimates are unavailable. Death is biologically possible from severe malnutrition or refeeding complications, but no robust ARFID-specific mortality rate should be entered. Recovery is possible—especially with early, presentation-matched treatment—but long-term remission and relapse probabilities are not well quantified. Potential adverse prognostic factors include severe nutritional compromise, prolonged illness, multiple presentations, ASD/anxiety/OCD/trauma comorbidity, persistent pain or GI disease, tube dependence, family accommodation, and limited specialist access. No prognostic molecular biomarker exists.

12. Treatment

Treatment algorithm

  1. Triage medical stability: hospitalize or use higher care for severe bradycardia, hypotension/orthostasis, hypothermia, syncope, serious electrolyte abnormalities, acute food refusal/dehydration, suicidality, or severe malnutrition.
  2. Restore nutrition: begin with accepted foods and oral supplements to stabilize energy intake; monitor refeeding risk; add targeted micronutrients.
  3. Treat maintaining mechanism: graded sensory exposure and food chaining; interoceptive/appetite work and scheduled eating for lack of interest; exposure/response prevention for fear.
  4. Mobilize caregivers and environment: structured meals, reduction of accommodation, school plans, and caregiver coaching.
  5. Treat comorbidity and relapse risk: address anxiety, OCD, depression, ASD-related needs, allergy, pain, and GI disease without reinforcing unnecessary avoidance.

A multidisciplinary team may include pediatrics/adolescent medicine, psychiatry/psychology, dietetics, nursing, occupational or speech-language therapy, gastroenterology, and allergy specialists. (nocerino2024developmentandmanagement pages 9-11, fonseca2024avoidantrestrictivefood pages 10-12)

Psychological interventions

CBT-AR is a modular four-stage treatment: psychoeducation/early change, treatment planning, mechanism-focused exposure, and relapse prevention. Youth and adult proof-of-concept studies reported reductions in PARDI severity, increased dietary variety, and weight gain among underweight participants; adult anxiety/depression did not consistently improve. The original MGH pilot enrolled 35 participants aged 10–65 for 20–30 outpatient sessions, but it was uncontrolled. (fonseca2024avoidantrestrictivefood pages 13-14, NCT02963220 chunk 1)

FBT-ARFID externalizes the disorder, empowers caregivers, and focuses behaviorally on changing eating. The Stanford efficacy trial randomized 98 medically stable children aged 6–12 at 75–88% expected body weight to 14 sessions of FBT-ARFID or time-matched nonspecific care over four months, with expected body weight and parental self-efficacy as primary outcomes. This is stronger design evidence, but registry completion does not itself establish superiority until analyzed results are published. Protocol PMID: 36460266; trial: https://clinicaltrials.gov/study/NCT04450771. (NCT04450771 chunk 1, NCT04450771 chunk 2)

Suggested MAXO mappings: cognitive behavioral therapy; family therapy; exposure therapy; dietary counseling; nutritional supplementation; enteral tube feeding; weight monitoring; laboratory monitoring; electrocardiography; psychiatric assessment. Exact MAXO identifiers should be checked against the current ontology release.

Nutrition and enteral support

Dietetic treatment calculates energy/fluid needs, repairs macro- and micronutrient gaps, schedules meals, and gradually expands variety. Oral nutrition is preferred. Enteral feeding can be lifesaving but should generally be medically necessary, goal-directed, and temporary; prolonged use may reduce expectations for oral eating and reinforce avoidance. (fonseca2024avoidantrestrictivefood pages 12-13, fonseca2024avoidantrestrictivefood pages 10-12)

Pharmacotherapy

No medication is FDA-approved specifically for ARFID. Drugs are adjuncts for appetite, anxiety, nausea, rigidity, or comorbidity—not substitutes for nutritional/behavioral treatment. Small reports describe mirtazapine, cyproheptadine, low-dose olanzapine, SSRIs, and buspirone. A small mirtazapine report found mean weekly BMI change increased from 0.10 before treatment to 0.23 after initiation, but confounding and absence of randomization preclude an efficacy claim. Olanzapine may increase appetite and reduce rigidity but has metabolic and neurologic risks. There is no ARFID-specific pharmacogenomic guidance. (fonseca2024avoidantrestrictivefood pages 13-14, fonseca2024avoidantrestrictivefood pages 12-13)

Recent and ongoing implementation research

  • NCT05954728 COUNTERACT: double-masked, randomized CBT-AR versus dietitian nutrition counseling; ages 10–18; actual n=53; 15 weeks; outcomes include food neophobia, PARDI, diet, and food-cue fMRI. https://clinicaltrials.gov/study/NCT05954728. (NCT05954728 chunk 1)
  • NCT04450771: FBT-ARFID versus nonspecific care; n=98; completed; results publication pending in the retrieved record. https://clinicaltrials.gov/study/NCT04450771. (NCT04450771 chunk 1)
  • NCT03778216: randomized crossover feasibility trial of FBT-ARFID in ages 5–12; n=28. https://clinicaltrials.gov/study/NCT03778216. (NCT03778216 chunk 1)
  • NCT02963220: single-group CBT-AR pilot; n=35; ages 10–65. Adult outcome paper PMID 34423319. https://clinicaltrials.gov/study/NCT02963220. (NCT02963220 chunk 1, NCT02963220 chunk 2)
  • NCT06110806: 20-session family-based mindfulness/interoceptive exposure; only 12 enrolled and the trial was terminated because of failure to agree on a risk-mitigation plan—not demonstrated inefficacy. https://clinicaltrials.gov/study/NCT06110806. (NCT06110806 chunk 1)

No gene, cell, RNA, targeted molecular, immunologic, or surgical therapy is indicated.

13. Prevention

Primary prevention: evidence is insufficient for a population program. Reasonable strategies include responsive/noncoercive feeding, varied age-appropriate exposure, prompt management of pain/dysphagia/allergy, avoidance of unnecessary elimination diets, and caregiver education after choking or allergic events.

Secondary prevention: screen high-risk groups—children with faltering growth, extreme selectivity, ASD/ADHD, anxiety, emetophobia, food allergy, eosinophilic/GI disease, prolonged tube feeding, or marked mealtime distress—and confirm diagnosis early with clinical interview. School and primary-care growth monitoring may detect consequences before severe malnutrition.

Tertiary prevention: monitor growth, diet and micronutrients; prevent refeeding syndrome; minimize prolonged tube dependence; maintain food exposures and relapse plans; address family accommodation and school participation; and monitor bone, pubertal, cardiovascular, and psychiatric complications. There is no vaccine, chemoprophylaxis, carrier screening, or reproductive genetic counseling specific to ARFID.

14. Other species and natural disease

No naturally occurring veterinary disorder equivalent to DSM-defined ARFID was identified. Animals can exhibit neophobia, conditioned taste aversion, sensory selectivity, low appetite, or post-traumatic feeding avoidance, but cannot reproduce the full human diagnosis, particularly self-reported motivation and psychosocial-impairment criteria. Therefore, no NCBI Taxon, VBO breed, orthologous causal gene, zoonotic transmission, or comparative Mendelian-disease annotation should be assigned specifically to ARFID.

15. Model organisms

There is no validated whole-disorder mouse, rat, zebrafish, invertebrate, organoid, or iPSC model. Component models—conditioned taste aversion, bitter-taste sensitivity, fear conditioning, altered appetite hormones, sensory hypersensitivity, or developmental restricted exposure—may test individual mechanisms. Their major limitation is poor construct validity for heterogeneous human motivations, family interactions, culture, language, and functional impairment. No ARFID-specific knockout, knock-in, humanized model, CRISPR screen, or model-organism repository entry was established in the retrieved evidence.

Evidence appraisal and knowledge-base cautions

The most authoritative recent synthesis retrieved was Fonseca et al., published June 2024 in Journal of Eating Disorders, DOI: https://doi.org/10.1186/s40337-024-01021-z. Its conclusion appropriately states that assessment tools and treatments “are still in the process of development and validation.” (fonseca2024avoidantrestrictivefood pages 14-15)

The strongest 2024 primary phenotyping evidence is Sanchez-Cerezo et al.’s national active-surveillance latent-class analysis. Its finding that the combined presentation was most common argues against encoding the three presentations as mutually exclusive disease subtypes. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2)

For database population, claims should be graded as follows:

  • Established: clinical diagnostic criteria; absence of weight/shape motivation; heterogeneous dimensional presentations; nutritional and psychosocial consequences.
  • Moderately supported: associations with ASD, anxiety, ADHD, GI disease and food allergy; sensory/fear/appetite maintenance mechanisms; benefit of structured multidisciplinary care.
  • Preliminary: specific neural-circuit and appetite-hormone abnormalities; treatment-response magnitudes; genetic loci.
  • Not established/not applicable: monogenic causal genes, pathogenic variants, molecular biomarkers, disease-specific omics signatures, approved pharmacotherapy, validated animal model, mortality rate, or population screening program.

References

  1. (fonseca2024avoidantrestrictivefood pages 1-2): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  2. (sanchezcerezo2024subtypesofavoidantrestrictive pages 1-2): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

  3. (fonseca2024avoidantrestrictivefood pages 13-14): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  4. (fonseca2024avoidantrestrictivefood pages 12-13): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  5. (fonseca2024avoidantrestrictivefood pages 4-6): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  6. (NCT06110806 chunk 2): Robyn Sysko. Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Icahn School of Medicine at Mount Sinai. 2023. ClinicalTrials.gov Identifier: NCT06110806

  7. (fonseca2024avoidantrestrictivefood pages 2-4): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  8. (sanchezcerezo2024subtypesofavoidantrestrictive pages 2-3): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

  9. (nocerino2024developmentandmanagement pages 4-6): Rita Nocerino, Caterina Mercuri, Vincenzo Bosco, Vincenza Giordano, Silvio Simeone, Assunta Guillari, and Teresa Rea. Development and management of avoidant/restrictive food intake disorder and food neophobia in pediatric patients with food allergy: a comprehensive review. Nutrients, 16:3034, Sep 2024. URL: https://doi.org/10.3390/nu16173034, doi:10.3390/nu16173034. This article has 16 citations.

  10. (tomaszek2025unravelingtheconnections pages 2-4): Natalia Tomaszek, Agata Dominika Urbaniak, Daniel Bałdyga, Kamila Chwesiuk, Stefan Modzelewski, and Napoleon Waszkiewicz. Unraveling the connections: eating issues, microbiome, and gastrointestinal symptoms in autism spectrum disorder. Nutrients, 17:486, Jan 2025. URL: https://doi.org/10.3390/nu17030486, doi:10.3390/nu17030486. This article has 36 citations.

  11. (fonseca2024avoidantrestrictivefood pages 6-7): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  12. (dolan2023anticipatoryandconsummatory pages 1-2): Sarah C. Dolan, P. Evelyna Kambanis, Casey M. Stern, Kendra R. Becker, Lauren Breithaupt, Julia Gydus, Sarah Smith, Madhusmita Misra, Nadia Micali, Elizabeth A. Lawson, Kamryn T. Eddy, and Jennifer J. Thomas. Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder. Journal of Eating Disorders, Nov 2023. URL: https://doi.org/10.1186/s40337-023-00921-w, doi:10.1186/s40337-023-00921-w. This article has 13 citations and is from a peer-reviewed journal.

  13. (dolan2023anticipatoryandconsummatory pages 8-9): Sarah C. Dolan, P. Evelyna Kambanis, Casey M. Stern, Kendra R. Becker, Lauren Breithaupt, Julia Gydus, Sarah Smith, Madhusmita Misra, Nadia Micali, Elizabeth A. Lawson, Kamryn T. Eddy, and Jennifer J. Thomas. Anticipatory and consummatory pleasure in avoidant/restrictive food intake disorder. Journal of Eating Disorders, Nov 2023. URL: https://doi.org/10.1186/s40337-023-00921-w, doi:10.1186/s40337-023-00921-w. This article has 13 citations and is from a peer-reviewed journal.

  14. (fonseca2024avoidantrestrictivefood pages 9-10): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  15. (fonseca2024avoidantrestrictivefood pages 10-12): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  16. (sanchezcerezo2024subtypesofavoidantrestrictive pages 3-4): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

  17. (NCT05954728 chunk 1): Jennifer Thomas. Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder. Massachusetts General Hospital. 2024. ClinicalTrials.gov Identifier: NCT05954728

  18. (NCT04450771 chunk 1): James Dale Lock. Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. Stanford University. 2020. ClinicalTrials.gov Identifier: NCT04450771

  19. (NCT03778216 chunk 1): James Dale Lock. Treating Avoidant/Restrictive Food Intake Disorder (ARFID) Using Family-Based Treatment. Stanford University. 2017. ClinicalTrials.gov Identifier: NCT03778216

  20. (NCT02963220 chunk 1): Jennifer Thomas. Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: A Treatment Development and Pilot Study. Massachusetts General Hospital. 2016. ClinicalTrials.gov Identifier: NCT02963220

  21. (NCT06110806 chunk 1): Robyn Sysko. Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder. Icahn School of Medicine at Mount Sinai. 2023. ClinicalTrials.gov Identifier: NCT06110806

  22. (fonseca2024avoidantrestrictivefood pages 14-15): Natasha K. O. Fonseca, Vitória D. Curtarelli, Juliana Bertoletti, Karla Azevedo, Tiago M. Cardinal, Júlia D. Moreira, and Luciana C. Antunes. Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. Journal of Eating Disorders, Jun 2024. URL: https://doi.org/10.1186/s40337-024-01021-z, doi:10.1186/s40337-024-01021-z. This article has 71 citations and is from a peer-reviewed journal.

  23. (sanchezcerezo2024subtypesofavoidantrestrictive pages 9-10): Javier Sanchez-Cerezo, Josephine Neale, Nikita Julius, Tim Croudace, Richard M. Lynn, Lee D. Hudson, and Dasha Nicholls. Subtypes of avoidant/restrictive food intake disorder in children and adolescents: a latent class analysis. eClinicalMedicine, 68:102440, Feb 2024. URL: https://doi.org/10.1016/j.eclinm.2024.102440, doi:10.1016/j.eclinm.2024.102440. This article has 54 citations and is from a peer-reviewed journal.

  24. (NCT04450771 chunk 2): James Dale Lock. Confirming the Efficacy/Mechanism of Family Therapy for Children With Low Weight ARFID. Stanford University. 2020. ClinicalTrials.gov Identifier: NCT04450771

  25. (che2025avoidantrestrictivefoodintake pages 13-15): Yunqiu Che, Shuhua Li, Xiaju Hu, Hongyan Hu, Can Zhang, and Chaozhu He. Avoidant/restrictive food intake disorder in adult patients with gastrointestinal diseases: a concept analysis using evolutionary approach. Risk Management and Healthcare Policy, 18:2063-2080, Jun 2025. URL: https://doi.org/10.2147/rmhp.s520802, doi:10.2147/rmhp.s520802. This article has 6 citations and is from a peer-reviewed journal.

  26. (nocerino2024developmentandmanagement pages 9-11): Rita Nocerino, Caterina Mercuri, Vincenzo Bosco, Vincenza Giordano, Silvio Simeone, Assunta Guillari, and Teresa Rea. Development and management of avoidant/restrictive food intake disorder and food neophobia in pediatric patients with food allergy: a comprehensive review. Nutrients, 16:3034, Sep 2024. URL: https://doi.org/10.3390/nu16173034, doi:10.3390/nu16173034. This article has 16 citations.

  27. (NCT02963220 chunk 2): Jennifer Thomas. Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: A Treatment Development and Pilot Study. Massachusetts General Hospital. 2016. ClinicalTrials.gov Identifier: NCT02963220

Artifacts